AXA/2025/FY/Financial supplement: Difference between revisions
Appearance
< AXA
Content deleted Content added
PlumBot: publish from draft |
PlumBot: publish from draft |
||
| Line 18: | Line 18: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Exchange rate time series by currency |
|||
|+ Average foreign exchange rates time series for fiscal years 1H24, FY24, 1H25, and FY25 |
|||
! style="text-align:left" | |
! style="text-align:left" | EUR |
||
! class="col-s" style="text-align:right" | 1H24 |
! class="col-s" style="text-align:right" | 1H24 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 83: | Line 83: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Discount rate 5Y time series by currency |
||
! style="text-align:left" | |
! style="text-align:left" | EUR |
||
! class="col-s" style="text-align:right" | Average 1H24 |
! class="col-s" style="text-align:right" | Average 1H24 |
||
! class="col-s" style="text-align:right" | Average FY24 |
! class="col-s" style="text-align:right" | Average FY24 |
||
| Line 130: | Line 130: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Discount rate 10Y time series by currency |
||
! style="text-align:left" | |
! style="text-align:left" | EUR |
||
! class="col-s" style="text-align:right" | Closing 1H24 |
! class="col-s" style="text-align:right" | Closing 1H24 |
||
! class="col-s" style="text-align:right" | Closing FY24 |
! class="col-s" style="text-align:right" | Closing FY24 |
||
| Line 179: | Line 179: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Group underlying earnings by line of business and net income build-up by business unit |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! colspan="4" style="text-align:center" | Group |
! colspan="4" style="text-align:center" | Group |
||
! colspan="4" style="text-align:center" | Property & |
! colspan="4" style="text-align:center" | Property & casualty |
||
! colspan="4" style="text-align:center" | Life & |
! colspan="4" style="text-align:center" | Life & health |
||
! style="text-align:center" | Asset |
! colspan="4" style="text-align:center" | Asset management {{footnote|1=AXA IM FY contribution presented in this document corresponds to its effective contribution to the Group’s results over the period of time when it was consolidated, i.e. until 1st July 2025.}} |
||
! style="text-align:center" | |
! colspan="4" style="text-align:center" | Holdings {{footnote|1=Includes Bank with Underlying Earnings Group Share of Euro -24 million as of 1H24, -55 million as of FY24, -24 million as of 1H25 and -54 million as of FY25.}} |
||
| ⚫ | |||
| ⚫ | |||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | 1H24 |
! class="col-s" style="text-align:right" | 1H24 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 255: | Line 253: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Combined |
| style="text-align:left" | Combined Ratio |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 277: | Line 275: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Technical |
| style="text-align:left" | Technical Margin |
||
| style="text-align:right" | 2,877 |
| style="text-align:right" | 2,877 |
||
| style="text-align:right" | 5,421 |
| style="text-align:right" | 5,421 |
||
| Line 299: | Line 297: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | '''Long-term |
| style="text-align:left" | '''Long-term Business''' |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 833: | Line 831: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Underlying earnings |
|+ Underlying earnings by geography build-up by geography {{footnote|1=Includes Bank with Underlying Earnings Group Share of Euro -24 million as of 1H24, -55 million as of FY24, -24 million as of 1H25 and -54 million as of FY25.}} |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! colspan="4" style="text-align:center" | Group |
! colspan="4" style="text-align:center" | Group |
||
! colspan="4" style="text-align:center" | France |
! colspan="4" style="text-align:center" | France |
||
| Line 840: | Line 838: | ||
! colspan="4" style="text-align:center" | AXA XL |
! colspan="4" style="text-align:center" | AXA XL |
||
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
||
! style="text-align:center" | AXA IM {{footnote|1=AXA IM FY contribution presented in this document corresponds to its effective contribution to the Group’s results over the period of time when it was consolidated, i.e. until 1st July 2025.}} |
! colspan="4" style="text-align:center" | AXA IM {{footnote|1=AXA IM FY contribution presented in this document corresponds to its effective contribution to the Group’s results over the period of time when it was consolidated, i.e. until 1st July 2025.}} |
||
| ⚫ | |||
! style="text-align:center" | AXA IM {{footnote|1=Includes Bank with Underlying Earnings Group Share of Euro -24 million as of 1H24, -55 million as of FY24, -24 million as of 1H25 and -54 million as of FY25.}} |
|||
| ⚫ | |||
| ⚫ | |||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | 1H24 |
! class="col-s" style="text-align:right" | 1H24 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 935: | Line 931: | ||
| style="text-align:right" | 2,107 |
| style="text-align:right" | 2,107 |
||
|- |
|- |
||
| style="text-align:left" | Combined |
| style="text-align:left" | Combined Ratio |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 965: | Line 961: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Technical |
| style="text-align:left" | Technical Margin |
||
| style="text-align:right" | 2,877 |
| style="text-align:right" | 2,877 |
||
| style="text-align:right" | 5,421 |
| style="text-align:right" | 5,421 |
||
| Line 995: | Line 991: | ||
| style="text-align:right" | 109 |
| style="text-align:right" | 109 |
||
|- |
|- |
||
| style="text-align:left" | '''Long-term |
| style="text-align:left" | '''Long-term Business''' |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 1,391: | Line 1,387: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Shares and UEPS build-up |
|||
|+ Shares and underlying earnings per share time series for fiscal years FY24 and FY25 |
|||
! style="text-align:left" | |
! style="text-align:left" | EUR |
||
! style="text-align:center" | Outstanding shares excluding treasury shares (a) {{footnote|1=Under IFRS, Treasury shares are not considered as outstanding shares. Treasury shares amounted to 35 million shares as of FY25 and 39 million shares as of FY24.}} |
! style="text-align:center" | Outstanding shares excluding treasury shares (a) {{footnote|1=Under IFRS, Treasury shares are not considered as outstanding shares. Treasury shares amounted to 35 million shares as of FY25 and 39 million shares as of FY24.}} |
||
! style="text-align:center" | Outstanding shares excluding treasury shares (a) |
! style="text-align:center" | Outstanding shares excluding treasury shares (a) |
||
| Line 1,547: | Line 1,543: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Property |
|+ Property & casualty underlying earnings by line of business build-up by line of business |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! colspan="4" style="text-align:center" | Total |
! colspan="4" style="text-align:center" | Total |
||
! colspan="4" style="text-align:center" | Commercial lines |
! colspan="4" style="text-align:center" | Commercial lines |
||
| Line 1,555: | Line 1,551: | ||
! colspan="4" style="text-align:center" | Intercompany eliminations |
! colspan="4" style="text-align:center" | Intercompany eliminations |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | 1H24 |
! class="col-s" style="text-align:right" | 1H24 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 2,265: | Line 2,261: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Property |
|+ Property & casualty underlying earnings by geography build-up by geography |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! colspan="4" style="text-align:center" | Total |
! colspan="4" style="text-align:center" | Total |
||
! colspan="4" style="text-align:center" | France |
! colspan="4" style="text-align:center" | France |
||
| Line 2,279: | Line 2,275: | ||
! style="text-align:center" | o/w AXA XL insurance |
! style="text-align:center" | o/w AXA XL insurance |
||
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
||
! colspan="4" style="text-align:center" | Transversal & |
! colspan="4" style="text-align:center" | Transversal & other |
||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | 1H24 |
! class="col-s" style="text-align:right" | 1H24 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 2,294: | Line 2,290: | ||
! class="col-s" style="text-align:right" | 1H25 |
! class="col-s" style="text-align:right" | 1H25 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
! |
! class="col-s" style="text-align:right" | 1H24 |
||
! |
! class="col-s" style="text-align:right" | o/w AXA XL insurance |
||
! |
! class="col-s" style="text-align:right" | FY24 |
||
! |
! class="col-s" style="text-align:right" | o/w AXA XL insurance |
||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
! class="col-s" style="text-align:right" | o/w AXA XL insurance |
|||
! class="col-s" style="text-align:right" | 1H24 |
! class="col-s" style="text-align:right" | 1H24 |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 3,153: | Line 3,153: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Life |
|+ Life & Health Underlying Earnings by Line of Business breakdown by line of business |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! colspan="4" style="text-align:center" | Total |
! colspan="4" style="text-align:center" | Total |
||
! colspan="4" style="text-align:center" | Life |
! colspan="4" style="text-align:center" | Life |
||
! colspan="4" style="text-align:center" | Health |
! colspan="4" style="text-align:center" | Health |
||
! style="text-align:center" | Employee |
! style="text-align:center" | Employee Benefits* (out of Total Life & Health) {{footnote|1=Employee Benefits include Group Protection and Group Health contracts.}} |
||
! colspan="3" style="text-align:center" | Employee |
! colspan="3" style="text-align:center" | Employee Benefits* (out of Total Life & Health) |
||
|- |
|- |
||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
| Line 3,797: | Line 3,797: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Life |
|+ Life & Health Underlying Earnings by Geography breakdown by geography |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! colspan="4" style="text-align:center" | Total |
! colspan="4" style="text-align:center" | Total |
||
| Line 3,804: | Line 3,804: | ||
! colspan="4" style="text-align:center" | AXA XL |
! colspan="4" style="text-align:center" | AXA XL |
||
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
||
! colspan="4" style="text-align:center" | Transversal & |
! colspan="4" style="text-align:center" | Transversal & Other |
||
|- |
|- |
||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
| Line 4,644: | Line 4,644: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Life |
|+ Life Underlying Earnings by Geography breakdown by geography |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! colspan="4" style="text-align:center" | Total |
! colspan="4" style="text-align:center" | Total |
||
| Line 4,651: | Line 4,651: | ||
! colspan="4" style="text-align:center" | AXA XL |
! colspan="4" style="text-align:center" | AXA XL |
||
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
||
! colspan="4" style="text-align:center" | Transversal & |
! colspan="4" style="text-align:center" | Transversal & Other |
||
|- |
|- |
||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
| Line 5,491: | Line 5,491: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Health |
|+ Health Underlying Earnings by Geography breakdown by geography |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! colspan="4" style="text-align:center" | Total |
! colspan="4" style="text-align:center" | Total |
||
| Line 5,498: | Line 5,498: | ||
! colspan="4" style="text-align:center" | AXA XL |
! colspan="4" style="text-align:center" | AXA XL |
||
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
! colspan="4" style="text-align:center" | Asia, Africa & EME-LATAM |
||
! colspan="4" style="text-align:center" | Transversal & |
! colspan="4" style="text-align:center" | Transversal & Other |
||
|- |
|- |
||
! style="text-align:left" | — |
! style="text-align:left" | — |
||
| Line 6,338: | Line 6,338: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Asset management |
|+ Asset management rollforward and build-up by type |
||
! style="text-align:left" | |
! style="text-align:left" | |
||
! colspan="2" style="text-align:center" | 1H24 |
! colspan="2" style="text-align:center" | 1H24 |
||
! colspan="2" style="text-align:center" | FY24 |
! colspan="2" style="text-align:center" | FY24 |
||
! colspan="2" style="text-align:center" | 1H25 |
! colspan="2" style="text-align:center" | 1H25 |
||
! style="text-align:center" | FY25 {{footnote|1=AXA IM FY contribution presented in this document corresponds to its effective contribution to the Group’s results over the period of time when it was consolidated, i.e. until 1st July 2025.}} |
! colspan="2" style="text-align:center" | FY25 {{footnote|1=AXA IM FY contribution presented in this document corresponds to its effective contribution to the Group’s results over the period of time when it was consolidated, i.e. until 1st July 2025.}} |
||
| ⚫ | |||
|- |
|- |
||
! style="text-align:left" | |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
! class="col-s" style="text-align:right" | o/w third party |
! class="col-s" style="text-align:right" | o/w third party |
||
| Line 6,356: | Line 6,355: | ||
! class="col-s" style="text-align:right" | o/w third party |
! class="col-s" style="text-align:right" | o/w third party |
||
|- |
|- |
||
| style="text-align:left" | '''Opening AUM (in |
| style="text-align:left" | '''Opening AUM (in EUR billion)''' |
||
| style="text-align:right" | '''843''' |
| style="text-align:right" | '''843''' |
||
| style="text-align:right" | '''332''' |
| style="text-align:right" | '''332''' |
||
| Line 6,406: | Line 6,405: | ||
| style="text-align:right" | -6 |
| style="text-align:right" | -6 |
||
|- |
|- |
||
| style="text-align:left" | '''Closing AUM (in |
| style="text-align:left" | '''Closing AUM (in EUR billion)''' |
||
| style="text-align:right" | '''859''' |
| style="text-align:right" | '''859''' |
||
| style="text-align:right" | '''340''' |
| style="text-align:right" | '''340''' |
||
| Line 6,622: | Line 6,621: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
| ⚫ | |+ Holdings Underlying Earnings¹ time series {{footnote|1=Includes Bank with Underlying Earnings Group Share of Euro -24 million as of 1H24, -55 million as of FY24, -24 million as of 1H25 and -54 million as of FY25.}} {{footnote|1=Includes exceptional cash remittances from the reinsurance treaties for the in-force Savings portfolio at AXA France (Euro +0.4 billion in 2024) and AXA Life Europe (Euro +0.2 billion in 2024).}} {{footnote|1=On top of annual share buy-back, includes Euro +3.5 billion share buy-back in 2025 to offset the earnings dilution resulting from the disposal of AXA IM and Euro +0.7 billion share buy-back in 2024 from the reinsurance treaties for the in-force Savings portfolio at AXA France (Euro +0.5 billion) and AXA Life Europe (Euro +0.2 billion).}} |
||
|+ Holdings underlying earnings (UE) build-up for first half 2024, fiscal year 2024, first half 2025 and fiscal year 2025 |
|||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | 1H24 |
! class="col-s" style="text-align:right" | 1H24 |
||
| Line 6,629: | Line 6,628: | ||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | Financial result |
| style="text-align:left" | Financial result |
||
| style="text-align:right" | 181 |
| style="text-align:right" | 181 |
||
| style="text-align:right" | 402 |
| style="text-align:right" | 402 |
||
| Line 6,635: | Line 6,634: | ||
| style="text-align:right" | 422 |
| style="text-align:right" | 422 |
||
|- |
|- |
||
| style="text-align:left" | Other revenues {{footnote|1=Includes |
| style="text-align:left" | Other revenues {{footnote|1=Includes liquid invested assets.}} |
||
| style="text-align:right" | 522 |
| style="text-align:right" | 522 |
||
| style="text-align:right" | 1,050 |
| style="text-align:right" | 1,050 |
||
| Line 6,641: | Line 6,640: | ||
| style="text-align:right" | 1,149 |
| style="text-align:right" | 1,149 |
||
|- |
|- |
||
| ⚫ | |||
| ⚫ | | |
||
| style="text-align:right" | -925 |
| style="text-align:right" | -925 |
||
| style="text-align:right" | -1,986 |
| style="text-align:right" | -1,986 |
||
| Line 6,677: | Line 6,676: | ||
| style="text-align:right" | 0 |
| style="text-align:right" | 0 |
||
|- |
|- |
||
| style="text-align:left" | '''Underlying earnings group share |
| style="text-align:left" | '''Underlying earnings group share''' |
||
| style="text-align:right" | '''-592''' |
| style="text-align:right" | '''-592''' |
||
| style="text-align:right" | '''-1,157''' |
| style="text-align:right" | '''-1,157''' |
||
| Line 6,689: | Line 6,688: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Activity Indicators by Line of Business time series by line of business |
|||
|+ Activity indicators breakdown by segment for first half 2024, fiscal year 2024, first half 2025 and fiscal year 2025 |
|||
! style="text-align:left" | |
! style="text-align:left" | |
||
! colspan="8" style="text-align:center" | 1H24 |
! colspan="8" style="text-align:center" | 1H24 |
||
| Line 6,699: | Line 6,698: | ||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
! class="col-s" style="text-align:right" | P&C |
! class="col-s" style="text-align:right" | P&C |
||
! class="col-s" style="text-align:right" | Life & |
! class="col-s" style="text-align:right" | Life & Health |
||
! class="col-s" style="text-align:right" | o/w employee benefits |
! class="col-s" style="text-align:right" | o/w employee benefits {{footnote|1=Employee Benefits include Group Protection and Group Health contracts.}} |
||
! class="col-s" style="text-align:right" | Life |
! class="col-s" style="text-align:right" | Life |
||
! class="col-s" style="text-align:right" | Health |
! class="col-s" style="text-align:right" | Health |
||
| Line 6,707: | Line 6,706: | ||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
! class="col-s" style="text-align:right" | P&C |
! class="col-s" style="text-align:right" | P&C |
||
! class="col-s" style="text-align:right" | Life & |
! class="col-s" style="text-align:right" | Life & Health |
||
! class="col-s" style="text-align:right" | o/w employee benefits |
! class="col-s" style="text-align:right" | o/w employee benefits {{footnote|1=Employee Benefits include Group Protection and Group Health contracts.}} |
||
! class="col-s" style="text-align:right" | Life |
! class="col-s" style="text-align:right" | Life |
||
! class="col-s" style="text-align:right" | Health |
! class="col-s" style="text-align:right" | Health |
||
| Line 6,715: | Line 6,714: | ||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
! class="col-s" style="text-align:right" | P&C |
! class="col-s" style="text-align:right" | P&C |
||
! class="col-s" style="text-align:right" | Life & |
! class="col-s" style="text-align:right" | Life & Health |
||
! class="col-s" style="text-align:right" | o/w employee benefits |
! class="col-s" style="text-align:right" | o/w employee benefits {{footnote|1=Employee Benefits include Group Protection and Group Health contracts.}} |
||
! class="col-s" style="text-align:right" | Life |
! class="col-s" style="text-align:right" | Life |
||
! class="col-s" style="text-align:right" | Health |
! class="col-s" style="text-align:right" | Health |
||
| Line 6,723: | Line 6,722: | ||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
! class="col-s" style="text-align:right" | P&C |
! class="col-s" style="text-align:right" | P&C |
||
! class="col-s" style="text-align:right" | Life & |
! class="col-s" style="text-align:right" | Life & Health |
||
! class="col-s" style="text-align:right" | o/w employee benefits |
! class="col-s" style="text-align:right" | o/w employee benefits {{footnote|1=Employee Benefits include Group Protection and Group Health contracts.}} |
||
! class="col-s" style="text-align:right" | Life |
! class="col-s" style="text-align:right" | Life |
||
! class="col-s" style="text-align:right" | Health |
! class="col-s" style="text-align:right" | Health |
||
| Line 6,832: | Line 6,831: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Other NBV {{footnote|1=Includes expected profits from short term Life & Health business, carried by Life entities, Pure Investment Contracts, NBV from Equity method entities as well as New Business Loss Components and Margin ceded to reinsurers.}} |
|||
| style="text-align:left" | Other NBV * |
|||
| style="text-align:right" | 456 |
| style="text-align:right" | 456 |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 6,972: | Line 6,971: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Activity Indicators by Geography time series by geography |
|||
|+ Activity indicators breakdown by geography for first half 2024, fiscal year 2024, first half 2025 and fiscal year 2025 |
|||
! style="text-align:left" | |
! style="text-align:left" | |
||
! colspan="7" style="text-align:center" | 1H24 |
! colspan="7" style="text-align:center" | 1H24 |
||
| Line 6,986: | Line 6,985: | ||
! class="col-s" style="text-align:right" | Asia, Africa & EME-LATAM |
! class="col-s" style="text-align:right" | Asia, Africa & EME-LATAM |
||
! class="col-s" style="text-align:right" | AXA IM |
! class="col-s" style="text-align:right" | AXA IM |
||
! class="col-s" style="text-align:right" | Transversal & |
! class="col-s" style="text-align:right" | Transversal & Other |
||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
! class="col-s" style="text-align:right" | France |
! class="col-s" style="text-align:right" | France |
||
| Line 6,993: | Line 6,992: | ||
! class="col-s" style="text-align:right" | Asia, Africa & EME-LATAM |
! class="col-s" style="text-align:right" | Asia, Africa & EME-LATAM |
||
! class="col-s" style="text-align:right" | AXA IM |
! class="col-s" style="text-align:right" | AXA IM |
||
! class="col-s" style="text-align:right" | Transversal & |
! class="col-s" style="text-align:right" | Transversal & Other |
||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
! class="col-s" style="text-align:right" | France |
! class="col-s" style="text-align:right" | France |
||
| Line 7,000: | Line 6,999: | ||
! class="col-s" style="text-align:right" | Asia, Africa & EME-LATAM |
! class="col-s" style="text-align:right" | Asia, Africa & EME-LATAM |
||
! class="col-s" style="text-align:right" | AXA IM |
! class="col-s" style="text-align:right" | AXA IM |
||
! class="col-s" style="text-align:right" | Transversal & |
! class="col-s" style="text-align:right" | Transversal & Other |
||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
! class="col-s" style="text-align:right" | France |
! class="col-s" style="text-align:right" | France |
||
| Line 7,007: | Line 7,006: | ||
! class="col-s" style="text-align:right" | Asia, Africa & EME-LATAM |
! class="col-s" style="text-align:right" | Asia, Africa & EME-LATAM |
||
! class="col-s" style="text-align:right" | AXA IM |
! class="col-s" style="text-align:right" | AXA IM |
||
! class="col-s" style="text-align:right" | Transversal & |
! class="col-s" style="text-align:right" | Transversal & Other |
||
|- |
|- |
||
| style="text-align:left" | Gross written premiums & other revenues |
| style="text-align:left" | Gross written premiums & other revenues |
||
| Line 7,099: | Line 7,098: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Other NBV {{footnote|1=Includes expected profits from short term Life & Health business, carried by Life entities, Pure Investment Contracts, NBV from Equity method entities as well as New Business Loss Components and Margin ceded to reinsurers.}} |
|||
| style="text-align:left" | Other NBV * |
|||
| style="text-align:right" | 456 |
| style="text-align:right" | 456 |
||
| style="text-align:right" | 275 |
| style="text-align:right" | 275 |
||
| Line 7,225: | Line 7,224: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Assets build-up |
|||
|+ Balance sheet assets breakdown for fiscal years 2024 and 2025 |
|||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 7,302: | Line 7,301: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Liabilities, non-controlling interests & shareholders' equity build-up |
|||
|+ Balance sheet liabilities and equity breakdown for fiscal years 2024 and 2025 |
|||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 7,373: | Line 7,372: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Contractual service margin (CSM) rollforward by |
|+ Contractual service margin (CSM) rollforward by business unit, pre-tax and post-tax, under IFRS 17 |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | FY23 restated |
! class="col-s" style="text-align:right" | FY23 restated |
||
! class="col-s" style="text-align:right" | New business CSM |
! class="col-s" style="text-align:right" | New business CSM |
||
! class="col-s" style="text-align:right" | Underlying return on inforce |
! class="col-s" style="text-align:right" | Underlying return on inforce |
||
| Line 7,381: | Line 7,380: | ||
! class="col-s" style="text-align:right" | Economic variance |
! class="col-s" style="text-align:right" | Economic variance |
||
! class="col-s" style="text-align:right" | Operating variance |
! class="col-s" style="text-align:right" | Operating variance |
||
! class="col-s" style="text-align:right" | Other {{footnote|1=Including scope changes and FX.}} |
! class="col-s" style="text-align:right" | Other {{footnote|1=Including scope changes and FX. ** Following the termination of the sale of a closed life and pensions portfolio at AXA Germany in 2024. It was classified as held for sale in 2023.}} |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
|- |
|- |
||
| Line 7,438: | Line 7,437: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Contractual service margin (CSM) rollforward by |
|+ Contractual service margin (CSM) rollforward by business unit, pre-tax and post-tax, under IFRS 17 {{footnote|1=Including scope changes and FX.}} |
||
! style="text-align:left" | EUR million |
! style="text-align:left" | EUR million |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 7,446: | Line 7,445: | ||
! class="col-s" style="text-align:right" | Economic variance |
! class="col-s" style="text-align:right" | Economic variance |
||
! class="col-s" style="text-align:right" | Operating variance |
! class="col-s" style="text-align:right" | Operating variance |
||
! class="col-s" style="text-align:right" | Other* |
! class="col-s" style="text-align:right" | Other {{footnote|1=Including scope changes and FX. ** Following the termination of the sale of a closed life and pensions portfolio at AXA Germany in 2024. It was classified as held for sale in 2023.}} |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| Line 7,505: | Line 7,504: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ General account invested assets breakdown by asset |
|+ General account invested assets as of FY25 breakdown by asset class {{footnote|1=1 Corporate bonds not rated by external rating agencies are reallocated under AXA’s internal ratings: AAA: Euro 0.03billion, AA: Euro 1billion, A: Euro 1,2 billion, BBB: Euro 3.6 billion, Below investment grade: Euro 5 billion.}} |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,580: | Line 7,579: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Duration gap sensitivity by rating |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! colspan="7" style="text-align:center" | Fair value by rating |
! colspan="7" style="text-align:center" | Fair value by rating |
||
| Line 7,635: | Line 7,634: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Breakdown by geographical exposure |
|+ Breakdown by geographical exposure of assets {{footnote|1=Corporate Bonds and Loans.}} |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,670: | Line 7,669: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Breakdown by industry |
|+ Breakdown by industry of assets |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,703: | Line 7,702: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Exposure to the financials breakdown by type {{footnote|1=Listed Equities1.}} |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
| Line 7,733: | Line 7,732: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Breakdown by asset domiciliation by geography |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,762: | Line 7,761: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Breakdown by industry by industry {{footnote|1=1 Including hedges.}} {{footnote|1=Real Estate.}} |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,797: | Line 7,796: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Breakdown by geographical exposure by geography |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,830: | Line 7,829: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Breakdown by type by type {{footnote|1=Private Equities1.}} |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,851: | Line 7,850: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Breakdown by asset domiciliation by geography {{footnote|1=1 Excluding Non-listed Equity.}} {{footnote|1=Mortgage Loans1,2.}} |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,870: | Line 7,869: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Breakdown by type by type {{footnote|1=1 Excludes banking operations and Euro 8 billion of Agency pools (Mortgage-backed securities issues by US Government Sponsored Enterprises).}} {{footnote|1=2 Loan to Value: 46%.}} |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Fair value |
! class="col-s" style="text-align:right" | Fair value |
||
| Line 7,887: | Line 7,886: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Change in group share consolidated shareholders' equity rollforward |
|||
|+ Shareholders' equity rollforward for fiscal year 2025 |
|||
! style="text-align:left" | |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
|- |
|- |
||
| style="text-align:left" | '''Shareholders' equity at beginning of the period {{footnote|1=Shareholders' equity excludes the other comprehensive income as well as the undated and deeply subordinated debt |
| style="text-align:left" | '''Shareholders' equity at beginning of the period {{footnote|1=Shareholders' equity excludes the other comprehensive income as well as the undated and deeply subordinated debt.}}''' |
||
| style="text-align:right" | '''49.9''' |
| style="text-align:right" | '''49.9''' |
||
|- |
|- |
||
| Line 7,930: | Line 7,929: | ||
| style="text-align:right" | -0.2 |
| style="text-align:right" | -0.2 |
||
|- |
|- |
||
| style="text-align:left" | '''Shareholders' equity at end of the period''' |
| style="text-align:left" | '''Shareholders' equity at end of the period {{footnote|1=Shareholders' equity excludes the undated and deeply subordinated debt. CSM is net of tax and Group Share.}}''' |
||
| style="text-align:right" | '''47.2''' |
| style="text-align:right" | '''47.2''' |
||
|} |
|} |
||
| Line 7,937: | Line 7,936: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Group share consolidated shareholders' equity build-up |
||
! style="text-align:left" | |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 7,986: | Line 7,985: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Unrealized gains and losses on invested assets (net of tax) breakdown by asset type |
||
! style="text-align:left" | |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
| Line 8,037: | Line 8,036: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ ROE ratio analysis |
|+ Return on equity (ROE) ratio analysis {{footnote|1=Financial interest treatment.}} |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 8,077: | Line 8,076: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Consolidated financial structure & debt gearing build-up |
|||
|+ Debt gearing ratio analysis for fiscal years 2024 and 2025 |
|||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 8,140: | Line 8,139: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Solvency II rollforward |
|||
|+ Solvency II eligible own funds (EOF), solvency capital requirement (SCR), and solvency II ratio rollforward for fiscal years 2024 and 2025 |
|||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 8,189: | Line 8,188: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ EOF tiering breakdown by tier |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | Total |
! class="col-s" style="text-align:right" | Total |
||
| Line 8,252: | Line 8,251: | ||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
|- |
|- |
||
| style="text-align:left" | Subject to transitional measures {{footnote|1=Transitional measures on basic own funds applied on subordinated debts eligible under Solvency I regulation. These subordinated debts were also eligible under Solvency II until December 31, 2025. They are no longer eligible since January 1, 2026.}} |
|||
| style="text-align:left" | Subject to transitional measures* |
|||
| style="text-align:right" | 4.5 |
| style="text-align:right" | 4.5 |
||
| style="text-align:right" | — |
| style="text-align:right" | — |
||
| Line 8,270: | Line 8,269: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ Solvency II |
|+ Solvency II key sensitivities (in pts) by scenario |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY24 |
! class="col-s" style="text-align:right" | FY24 |
||
| Line 8,321: | Line 8,320: | ||
<div style="overflow-x:auto"> |
<div style="overflow-x:auto"> |
||
{| class="wikitable fintable" |
{| class="wikitable fintable" |
||
|+ |
|+ Reconciliation IFRS17/9 shareholders' equity to Solvency II eligible own funds |
||
! style="text-align:left" | EUR billion |
! style="text-align:left" | EUR billion |
||
! class="col-s" style="text-align:right" | FY25 |
! class="col-s" style="text-align:right" | FY25 |
||
Latest revision as of 23:56, 13 June 2026
| Document info | |
|---|---|
| Organization | AXA |
| Year | 2025 |
| Period | FY |
| Period label | FY25 |
| Document type | Financial supplement |
| Publication date | 2026-02-26 |
| Language | English |
| Source | Original URL |
| Archive | .md file |
AXA Full Year 2025 financial supplement.
Market Data
| EUR | 1H24 | FY24 | 1H25 | FY25 | Average 1H24 | Average FY24 | Average 1H25 | Average FY25 |
|---|---|---|---|---|---|---|---|---|
| USD | 1.07 | 1.04 | 1.17 | 1.17 | 1.08 | 1.08 | 1.09 | 1.13 |
| JPY | 172 | 163 | 170 | 184 | 165 | 164 | 162 | 169 |
| GBP | 0.85 | 0.83 | 0.86 | 0.87 | 0.85 | 0.85 | 0.84 | 0.86 |
| CHF | 0.96 | 0.94 | 0.93 | 0.93 | 0.96 | 0.95 | 0.94 | 0.94 |
| HKD | 8.37 | 8.04 | 9.21 | 9.14 | 8.45 | 8.44 | 8.53 | 8.82 |
| EUR | Average 1H24 | Average FY24 | Average 1H25 | Average FY25 |
|---|---|---|---|---|
| EUR | 2.79% | 2.84% | 2.57% | 2.59% |
| USD | 4.35% | 4.41% | 4.40% | 4.23% |
| JPY | 0.22% | 0.42% | 0.89% | 1.01% |
| GBP | 4.00% | 4.25% | 4.38% | 4.31% |
| CHF | 1.05% | 0.82% | 0.18% | 0.16% |
| HKD | 3.75% | 3.67% | 3.45% | 3.18% |
| EUR | Closing 1H24 | Closing FY24 | Closing 1H25 | Closing FY25 |
|---|---|---|---|---|
| EUR | 3.06% | 2.71% | 2.91% | 3.17% |
| USD | 4.54% | 4.66% | 4.43% | 4.45% |
| JPY | 1.04% | 1.07% | 1.44% | 2.08% |
| GBP | 4.27% | 4.48% | 4.56% | 4.55% |
| CHF | 0.98% | 0.38% | 0.53% | 0.67% |
| HKD | 3.79% | 3.91% | 3.02% | 3.21% |
UE by LOB and Net Income
| EUR million | Group | Property & casualty | Life & health | Asset management (footnote: AXA IM FY contribution presented in this document corresponds to its effective contribution to the Group’s results over the period of time when it was consolidated, i.e. until 1st July 2025.) | Holdings (footnote: Includes Bank with Underlying Earnings Group Share of Euro -24 million as of 1H24, -55 million as of FY24, -24 million as of 1H25 and -54 million as of FY25.) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR million | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 |
| Short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Revenues | 35,273 | 72,104 | 37,209 | 75,071 | 27,294 | 55,898 | 28,697 | 57,656 | 7,979 | 16,207 | 8,512 | 17,416 | — | — | — | — | — | — | — | — |
| Combined Ratio | — | — | — | — | 90.2% | 91.0% | 90.0% | 90.6% | 97.6% | 97.4% | 97.1% | 97.2% | — | — | — | — | — | — | — | — |
| Technical Margin | 2,877 | 5,421 | 3,107 | 5,888 | 2,682 | 5,006 | 2,859 | 5,409 | 195 | 415 | 248 | 479 | — | — | — | — | — | — | — | — |
| Long-term Business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CSM release | 1,395 | 2,775 | 1,428 | 2,954 | — | — | — | — | 1,395 | 2,775 | 1,428 | 2,954 | — | — | — | — | — | — | — | — |
| Technical experience | -64 | -95 | -30 | -150 | — | — | — | — | -64 | -95 | -30 | -150 | — | — | — | — | — | — | — | — |
| Financial result & other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result | 2,064 | 3,971 | 2,148 | 4,013 | 1,324 | 2,559 | 1,343 | 2,631 | 536 | 975 | 563 | 946 | 24 | 35 | 14 | 14 | 181 | 402 | 228 | 422 |
| Other revenues | 1,459 | 3,054 | 1,625 | 2,167 | — | — | — | — | — | — | — | — | 937 | 2,004 | 1,018 | 1,018 | 522 | 1,050 | 607 | 1,149 |
| Other expenses | -1,624 | -3,479 | -1,868 | -2,900 | — | — | — | — | — | — | — | — | -698 | -1,493 | -793 | -793 | -925 | -1,986 | -1,075 | -2,107 |
| Debt financing charges | -471 | -948 | -452 | -928 | — | — | — | — | — | — | — | — | — | — | — | — | -471 | -948 | -452 | -928 |
| Underlying earnings before tax | 5,638 | 10,700 | 5,958 | 11,044 | 4,006 | 7,565 | 4,202 | 8,040 | 2,061 | 4,070 | 2,209 | 4,229 | 263 | 546 | 239 | 239 | -693 | -1,482 | -692 | -1,464 |
| Tax | -1,427 | -2,662 | -1,503 | -2,644 | -1,046 | -1,952 | -1,074 | -2,060 | -412 | -874 | -462 | -800 | -69 | -160 | -68 | -68 | 100 | 324 | 101 | 284 |
| Income from affiliates & other | 122 | 218 | 111 | 168 | 2 | 3 | 1 | 3 | 103 | 186 | 101 | 157 | 16 | 29 | 8 | 8 | 0 | 0 | 0 | 0 |
| Minority interests | -89 | -179 | -101 | -199 | -56 | -106 | -63 | -111 | -27 | -60 | -34 | -85 | -6 | -13 | -4 | -4 | 0 | 0 | 0 | 0 |
| Underlying earnings group share | 4,244 | 8,078 | 4,465 | 8,368 | 2,908 | 5,510 | 3,067 | 5,872 | 1,725 | 3,323 | 1,814 | 3,501 | 204 | 402 | 175 | 175 | -592 | -1,157 | -591 | -1,180 |
| Underlying earnings growth rate (constant FX) | 4% | 7% | 6% | 6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying ROE | 16.6% | 15.2% | 17.5% | 16.0% | — | 16.2% | — | 17.3% | — | 13.6% | — | 14.4% | — | 26.0% | — | n.a. | — | — | — | — |
| Net realized capital gains & losses | 93 | 195 | 66 | 138 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Change in fair value of assets & derivatives | -43 | 83 | -467 | -813 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Amortization of customer intangibles | -50 | -131 | -48 | -86 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Integration and restructuring costs | -78 | -240 | -63 | -197 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Exceptional items | -147 | -99 | -30 | 2,386 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income group share | 4,020 | 7,886 | 3,922 | 9,797 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Deeply subordinated and undated subordinated debt charges | -106 | -201 | -86 | -174 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying earnings for EPS calculation | 4,138 | 7,877 | 4,379 | 8,195 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income for EPS calculation | 3,914 | 7,685 | 3,836 | 9,623 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
UE by Geography
| EUR million | Group | France | Europe | AXA XL | Asia, Africa & EME-LATAM | AXA IM (footnote: AXA IM FY contribution presented in this document corresponds to its effective contribution to the Group’s results over the period of time when it was consolidated, i.e. until 1st July 2025.) | Transversal & other | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR million | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 |
| Short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Revenues | 35,273 | 72,104 | 37,209 | 75,071 | 9,046 | 18,698 | 9,567 | 19,555 | 11,839 | 24,005 | 12,661 | 25,724 | 9,022 | 18,530 | 9,428 | 18,699 | 4,312 | 8,750 | 4,478 | 8,986 | — | — | — | — | 1,053 | 2,122 | 1,075 | 2,107 |
| Combined Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Technical Margin | 2,877 | 5,421 | 3,107 | 5,888 | 692 | 1,470 | 658 | 1,485 | 998 | 1,957 | 1,176 | 2,357 | 1,111 | 1,820 | 1,074 | 1,928 | 70 | 81 | 150 | 9 | — | — | — | — | 6 | 93 | 49 | 109 |
| Long-term Business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CSM release | 1,395 | 2,775 | 1,428 | 2,954 | 407 | 823 | 419 | 895 | 468 | 920 | 471 | 984 | 4 | 3 | 0 | 1 | 516 | 1,029 | 538 | 1,074 | — | — | — | — | 0 | 0 | 0 | 0 |
| Technical experience | -64 | -95 | -30 | -150 | -40 | -96 | -37 | -81 | -11 | -8 | 8 | -70 | 3 | 2 | 0 | -5 | -17 | 7 | -1 | 6 | — | — | — | — | 0 | 0 | 0 | 0 |
| Financial result & other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result | 2,064 | 3,971 | 2,148 | 4,013 | 350 | 613 | 380 | 667 | 784 | 1,486 | 765 | 1,398 | 283 | 616 | 308 | 651 | 382 | 741 | 425 | 782 | 24 | 35 | 14 | 14 | 241 | 480 | 255 | 502 |
| Other revenues | 1,459 | 3,054 | 1,625 | 2,167 | 53 | 108 | 44 | 91 | -18 | -32 | -8 | -12 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -3 | 937 | 2,004 | 1,018 | 1,018 | 488 | 974 | 573 | 1,073 |
| Other expenses | -1,624 | -3,479 | -1,868 | -2,900 | -83 | -180 | -79 | -168 | -10 | -25 | -6 | -3 | 0 | 0 | 0 | 0 | -9 | -20 | -14 | -26 | -698 | -1,493 | -793 | -793 | -823 | -1,761 | -976 | -1,910 |
| Debt financing charges | -471 | -948 | -452 | -928 | 0 | 0 | 0 | 0 | -1 | -2 | -1 | -2 | -16 | -33 | -16 | -32 | -7 | -12 | -4 | -6 | — | — | — | — | -447 | -902 | -431 | -887 |
| Underlying earnings before tax | 5,638 | 10,700 | 5,958 | 11,044 | 1,380 | 2,738 | 1,384 | 2,888 | 2,210 | 4,297 | 2,406 | 4,651 | 1,385 | 2,409 | 1,366 | 2,543 | 935 | 1,826 | 1,093 | 1,835 | 263 | 546 | 239 | 239 | -535 | -1,116 | -530 | -1,113 |
| Tax | -1,427 | -2,662 | -1,503 | -2,644 | -350 | -676 | -308 | -665 | -536 | -1,004 | -568 | -1,039 | -355 | -588 | -342 | -650 | -205 | -443 | -294 | -434 | -69 | -160 | -68 | -68 | 88 | 209 | 76 | 212 |
| Income from affiliates & other | 122 | 218 | 111 | 168 | 4 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 102 | 181 | 103 | 160 | 16 | 29 | 8 | 8 | 0 | 0 | 0 | 0 |
| Minority interests | -89 | -179 | -101 | -199 | 0 | 0 | 0 | 0 | -48 | -105 | -56 | -126 | 0 | 0 | 0 | 0 | -34 | -60 | -39 | -68 | -6 | -13 | -4 | -4 | 0 | 0 | -1 | -2 |
| Underlying earnings group share | 4,244 | 8,078 | 4,465 | 8,368 | 1,034 | 2,071 | 1,076 | 2,224 | 1,626 | 3,187 | 1,782 | 3,486 | 1,030 | 1,820 | 1,024 | 1,893 | 798 | 1,504 | 862 | 1,493 | 204 | 402 | 175 | 175 | -447 | -907 | -455 | -903 |
| EUR | Outstanding shares excluding treasury shares (a) (footnote: Under IFRS, Treasury shares are not considered as outstanding shares. Treasury shares amounted to 35 million shares as of FY25 and 39 million shares as of FY24.) | Outstanding shares excluding treasury shares (a) | Weighted average number | |
|---|---|---|---|---|
| — | FY24 | FY25 | FY24 | FY25 |
| Basic number of shares | — | — | — | — |
| As of beginning of period | 2,226.2 | 2,175.4 | 2,226.2 | 2,175.4 |
| Increase of capital dedicated to employees | 12.9 | 12.7 | 0.9 | 1.0 |
| Exercise of stock-options | 2.6 | 1.1 | 1.4 | 0.6 |
| Other movement of treasury shares | 4.6 | 4.2 | 17.5 | 6.3 |
| Capital increase / (decrease) | -70.9 | -138.0 | -55.2 | -64.9 |
| As at end of period | 2,175.4 | 2,055.4 | — | — |
| During the period | — | — | 2,190.8 | 2,118.3 |
| Fully diluted number of shares | — | — | — | — |
| Stock options | — | — | 0.8 | 0.6 |
| Performance shares | — | — | 5.6 | 5.1 |
| During the period (A) | — | — | 2,197.1 | 2,124.0 |
| Earnings group share: | — | — | — | — |
| Net income | — | — | 7,886 | 9,797 |
| Underlying earnings | — | — | 8,078 | 8,368 |
| Impact of undated and deeply subordinated debts: | — | — | — | — |
| Undated and deeply subordinated debt charges | — | — | -201 | -174 |
| Earnings for EPS calculation: | — | — | — | — |
| Net income for EPS calculation (B) | — | — | 7,685 | 9,623 |
| Underlying earnings for EPS calculation (C) | — | — | 7,877 | 8,195 |
| Fully diluted euro per share (EPS) | — | — | — | — |
| EPS (B/A) | — | — | 3.50 | 4.53 |
| Underlying EPS (C/A) | — | — | 3.59 | 3.86 |
P&C UE by Sub LOB
| EUR million | Total | Commercial lines | Personal lines | AXA XL reinsurance | Intercompany eliminations | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR million | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 |
| Short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Revenues | 27,294 | 55,898 | 28,697 | 57,656 | 18,657 | 38,019 | 19,575 | 39,090 | 9,144 | 18,705 | 9,513 | 19,276 | 1,155 | 2,394 | 1,299 | 2,493 | -1,662 | -3,220 | -1,689 | -3,203 |
| Current accident year loss ratio | 67.0% | 67.7% | 66.7% | 66.9% | 68.1% | 68.8% | 68.0% | 68.0% | 69.8% | 70.0% | 68.8% | 69.1% | 69.7% | 70.6% | 70.8% | 71.9% | — | — | — | — |
| Undiscounted current accident year loss ratio (excl. nat cats) | 67.4% | 67.4% | 67.0% | 67.0% | 69.2% | 69.4% | 69.3% | 68.8% | 68.8% | 68.5% | 67.5% | 67.9% | 68.0% | 67.9% | 69.4% | 71.5% | — | — | — | — |
| Undiscounted current accident year nat cats | 3.6% | 3.8% | 3.5% | 3.4% | 2.7% | 2.9% | 2.7% | 2.6% | 4.0% | 4.1% | 3.8% | 3.6% | 10.6% | 10.4% | 9.2% | 8.7% | — | — | — | — |
| Current accident year discounting | -3.9% | -3.6% | -3.9% | -3.5% | -3.7% | -3.5% | -3.9% | -3.5% | -3.0% | -2.6% | -2.6% | -2.4% | -8.8% | -7.7% | -7.8% | -8.3% | — | — | — | — |
| Prior year reserve development ratio | -1.5% | -1.6% | -1.1% | -1.1% | -1.1% | -1.2% | -1.3% | -0.8% | -2.3% | -1.8% | -0.6% | -1.6% | -1.1% | -0.8% | -0.3% | 0.0% | — | — | — | — |
| Expense ratio | 24.7% | 25.0% | 24.5% | 24.8% | 23.1% | 23.6% | 23.2% | 23.5% | 25.5% | 25.7% | 25.1% | 25.2% | 10.0% | 9.9% | 9.1% | 9.4% | — | — | — | — |
| Combined ratio | 90.2% | 91.0% | 90.0% | 90.6% | 90.1% | 91.1% | 89.9% | 90.7% | 92.9% | 93.9% | 93.3% | 92.8% | 78.7% | 79.7% | 79.6% | 81.4% | — | — | — | — |
| Technical margin | 2,682 | 5,006 | 2,859 | 5,409 | 1,850 | 3,372 | 1,968 | 3,616 | 645 | 1,136 | 638 | 1,392 | 246 | 486 | 265 | 464 | -60 | 12 | -12 | -63 |
| Long-term business (footnote: For long-term business.) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CSM release | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Technical experience | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result & other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result | 1,324 | 2,559 | 1,343 | 2,631 | 993 | 1,831 | 1,004 | 1,941 | 240 | 538 | 275 | 523 | 119 | 210 | 85 | 186 | -28 | -20 | -20 | -20 |
| Investment income | 1,967 | 3,731 | 2,088 | 3,988 | 1,427 | 2,625 | 1,512 | 2,864 | 366 | 761 | 422 | 794 | 202 | 365 | 174 | 350 | -28 | -20 | -20 | -20 |
| Insurance finance expenses | -643 | -1,172 | -745 | -1,358 | -434 | -794 | -508 | -922 | -126 | -223 | -148 | -272 | -83 | -155 | -90 | -163 | 0 | 0 | 0 | 0 |
| Other revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt financing charges | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying earnings before tax | 4,006 | 7,565 | 4,202 | 8,040 | 2,843 | 5,203 | 2,973 | 5,557 | 886 | 1,674 | 913 | 1,914 | 365 | 696 | 349 | 650 | -87 | -8 | -33 | -82 |
| Tax | -1,046 | -1,952 | -1,074 | -2,060 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Income from affiliates & other | 2 | 3 | 1 | 3 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Minority interests | -56 | -106 | -63 | -111 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying earnings group share | 2,908 | 5,510 | 3,067 | 5,872 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Closing invested assets | 113,515 | 118,104 | 116,895 | 117,507 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| o/w VFA | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| o/w non VFA | 113,515 | 118,104 | 116,895 | 117,507 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| For short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Liabilities for remaining coverage net of reinsurance | 19,284 | 16,006 | 19,766 | 16,040 | 12,070 | 9,480 | 12,240 | 9,127 | 6,369 | 5,478 | 6,831 | 5,871 | 1,572 | 1,075 | 1,436 | 1,009 | -728 | -27 | -740 | 32 |
| Best Estimate for incurred Claims net of reinsurance (footnote: Best Estimate Liabilities net of reinsurance.) | 69,800 | 71,751 | 70,215 | 70,567 | 45,710 | 46,570 | 46,591 | 47,002 | 17,809 | 18,308 | 17,781 | 17,402 | 6,704 | 6,830 | 6,290 | 6,198 | -423 | 43 | -447 | -35 |
P&C UE by Geography
| EUR million | Total | France | Europe | AXA XL | o/w AXA XL insurance | FY24 | o/w AXA XL insurance | AXA XL | o/w AXA XL insurance | FY25 | o/w AXA XL insurance | Asia, Africa & EME-LATAM | Transversal & other | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR million | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | o/w AXA XL insurance | FY24 | o/w AXA XL insurance | 1H25 | o/w AXA XL insurance | FY25 | o/w AXA XL insurance | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 |
| Short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Revenues | 27,294 | 55,898 | 28,697 | 57,656 | 4,393 | 9,194 | 4,697 | 9,768 | 10,060 | 20,400 | 10,610 | 21,305 | 9,022 | 7,867 | 18,530 | 16,136 | 9,428 | 8,129 | 18,699 | 16,207 | 2,855 | 5,825 | 2,975 | 5,949 | 963 | 1,948 | 987 | 1,935 |
| Current accident year loss ratio | 67.0% | 67.7% | 66.7% | 66.9% | 69.4% | 68.9% | 70.6% | 70.1% | 66.5% | 66.9% | 64.7% | 65.1% | 67.5% | 67.2% | 69.2% | 69.0% | 68.4% | 68.0% | 68.8% | 68.3% | 68.6% | 69.3% | 68.2% | 69.6% | 53.2% | 51.0% | 48.0% | 44.6% |
| Undiscounted current accident year loss ratio (excl. nat cats) | 67.4% | 67.4% | 67.0% | 67.0% | 71.3% | 69.7% | 70.6% | 70.2% | 65.0% | 65.5% | 64.1% | 64.3% | 68.8% | 68.9% | 69.3% | 69.5% | 69.7% | 69.8% | 69.8% | 69.6% | 70.0% | 70.4% | 69.7% | 70.2% | 52.9% | 51.1% | 48.0% | 44.5% |
| Undiscounted current accident year nat cats | 3.6% | 3.8% | 3.5% | 3.4% | 3.4% | 3.8% | 4.8% | 4.5% | 4.5% | 4.1% | 3.3% | 3.1% | 3.8% | 2.8% | 4.6% | 3.8% | 4.2% | 3.4% | 3.9% | 3.1% | 0.8% | 0.9% | 0.8% | 1.6% | 1.4% | 1.1% | 1.3% | 1.2% |
| Current accident year discounting | -3.9% | -3.6% | -3.9% | -3.5% | -5.3% | -4.6% | -4.8% | -4.6% | -3.1% | -2.8% | -2.7% | -2.3% | -5.1% | -4.6% | -4.7% | -4.2% | -5.5% | -5.2% | -4.9% | -4.4% | -2.2% | -2.0% | -2.3% | -2.2% | -1.1% | -1.2% | -1.2% | -1.1% |
| Prior year reserve development ratio | -1.5% | -1.6% | -1.1% | -1.1% | -3.5% | -3.9% | -2.6% | -2.9% | -2.1% | -2.1% | -1.1% | -1.3% | -0.1% | 0.0% | -0.1% | 0.0% | -0.2% | -0.2% | 0.0% | 0.0% | -0.1% | 0.1% | -1.0% | -0.2% | -3.7% | -5.7% | -4.0% | -1.9% |
| Expense ratio | 24.7% | 25.0% | 24.5% | 24.8% | 21.9% | 21.9% | 20.7% | 20.4% | 25.9% | 26.2% | 26.0% | 26.2% | 20.3% | 21.8% | 21.0% | 22.7% | 20.4% | 22.2% | 20.9% | 22.6% | 29.4% | 29.6% | 29.0% | 29.8% | 50.5% | 50.9% | 52.5% | 52.8% |
| Combined ratio | 90.2% | 91.0% | 90.0% | 90.6% | 87.8% | 86.8% | 88.6% | 87.5% | 90.3% | 91.0% | 89.6% | 90.0% | 87.7% | 89.0% | 90.2% | 91.7% | 88.6% | 90.0% | 89.7% | 91.0% | 98.0% | 99.1% | 96.2% | 99.2% | 100.1% | 96.2% | 96.5% | 95.5% |
| Technical margin | 2,682 | 5,006 | 2,859 | 5,409 | 538 | 1,212 | 533 | 1,220 | 977 | 1,844 | 1,104 | 2,127 | 1,111 | 865 | 1,820 | 1,335 | 1,074 | 809 | 1,928 | 1,464 | 57 | 55 | 114 | 48 | -1 | 74 | 35 | 86 |
| Long-term business (footnote: For long-term business.) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CSM release | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Technical experience | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result & other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result | 1,324 | 2,559 | 1,343 | 2,631 | 251 | 421 | 261 | 468 | 473 | 912 | 461 | 876 | 273 | 159 | 596 | 387 | 298 | 213 | 632 | 445 | 242 | 484 | 261 | 530 | 86 | 146 | 62 | 125 |
| Investment income | 1,967 | 3,731 | 2,088 | 3,988 | 334 | 572 | 373 | 675 | 658 | 1,244 | 667 | 1,257 | 614 | 416 | 1,233 | 868 | 681 | 507 | 1,331 | 981 | 261 | 518 | 292 | 585 | 100 | 164 | 74 | 140 |
| Insurance finance expenses | -643 | -1,172 | -745 | -1,358 | -83 | -151 | -112 | -207 | -185 | -332 | -206 | -381 | -341 | -257 | -637 | -481 | -384 | -294 | -699 | -536 | -20 | -35 | -31 | -55 | -14 | -18 | -12 | -15 |
| Other revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt financing charges | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying earnings before tax | 4,006 | 7,565 | 4,202 | 8,040 | 788 | 1,633 | 794 | 1,688 | 1,450 | 2,757 | 1,564 | 3,002 | 1,384 | 1,024 | 2,417 | 1,721 | 1,372 | 1,022 | 2,560 | 1,910 | 299 | 539 | 375 | 579 | 85 | 220 | 97 | 211 |
| Tax | -1,046 | -1,952 | -1,074 | -2,060 | -249 | -472 | -220 | -451 | -352 | -671 | -384 | -734 | -352 | -257 | -588 | -457 | -339 | -252 | -647 | -482 | -77 | -159 | -110 | -170 | -15 | -62 | -21 | -58 |
| Income from affiliates & other | 2 | 3 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 3 | 0 | 0 | 0 | 0 |
| Minority interests | -56 | -106 | -63 | -111 | 0 | 0 | 0 | 0 | -25 | -57 | -28 | -52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -30 | -49 | -34 | -57 | 0 | 0 | -1 | -2 |
| Underlying earnings group share | 2,908 | 5,510 | 3,067 | 5,872 | 539 | 1,161 | 574 | 1,237 | 1,073 | 2,029 | 1,152 | 2,216 | 1,032 | 767 | 1,828 | 1,264 | 1,032 | 770 | 1,913 | 1,427 | 194 | 334 | 233 | 355 | 70 | 158 | 75 | 151 |
| For short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Liabilities for remaining coverage net of reinsurance | 19,284 | 16,006 | 19,766 | 16,040 | 2,153 | 1,712 | 2,221 | 1,783 | 7,151 | 5,166 | 7,591 | 5,534 | 7,478 | 5,905 | 7,028 | 5,948 | 7,315 | 5,879 | 6,467 | 5,461 | 1,802 | 1,834 | 1,935 | 2,024 | 700 | 266 | 705 | 231 |
| Best estimate for incurred claims net of reinsurance (footnote: Best Estimate Liabilities net of reinsurance.) | 69,800 | 71,751 | 70,215 | 70,567 | 13,485 | 13,889 | 13,900 | 13,882 | 24,834 | 25,955 | 26,003 | 25,737 | 24,865 | 18,223 | 25,915 | 19,146 | 24,533 | 18,295 | 25,044 | 18,897 | 3,385 | 3,640 | 3,510 | 3,804 | 3,231 | 2,351 | 2,269 | 2,101 |
L&H UE by LOB
| EUR million | Total | Life | Health | Employee Benefits* (out of Total Life & Health) (footnote: Employee Benefits include Group Protection and Group Health contracts.) | Employee Benefits* (out of Total Life & Health) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 |
| Short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Revenues | 7,979 | 16,207 | 8,512 | 17,416 | 2,112 | 4,247 | 2,211 | 4,444 | 5,867 | 11,960 | 6,301 | 12,972 | 5,592 | 11,482 | 5,931 | 12,035 |
| Combined ratio | 97.6% | 97.4% | 97.1% | 97.2% | 94.5% | 95.5% | 95.2% | 95.4% | 98.6% | 98.1% | 97.8% | 97.9% | 98.2% | 97.8% | 97.4% | 97.1% |
| Technical margin | 195 | 415 | 248 | 479 | 116 | 191 | 107 | 206 | 79 | 224 | 141 | 273 | 101 | 248 | 156 | 347 |
| Long-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CSM release | 1,395 | 2,775 | 1,428 | 2,954 | 1,136 | 2,253 | 1,158 | 2,415 | 259 | 522 | 270 | 539 | 58 | 110 | 59 | 107 |
| Technical experience | -64 | -95 | -30 | -150 | -71 | -98 | -28 | -139 | 7 | 3 | -2 | -11 | 17 | 37 | 22 | 38 |
| Actual vs. expected cash flows | 9 | -15 | 12 | 39 | -4 | -33 | 10 | 37 | 13 | 18 | 2 | 2 | -3 | -2 | -5 | -8 |
| Risk adjustment release | 30 | 59 | 44 | 72 | 25 | 51 | 37 | 59 | 4 | 8 | 7 | 13 | 2 | 4 | 7 | 8 |
| Changes in onerous contracts | -32 | 6 | -12 | -29 | -30 | 9 | -10 | -25 | -1 | -2 | -2 | -4 | 0 | 0 | 0 | 0 |
| Other long-term | -72 | -145 | -74 | -232 | -63 | -124 | -65 | -211 | -8 | -21 | -9 | -22 | 19 | 35 | 20 | 38 |
| Financial result & other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result | 536 | 975 | 563 | 946 | 454 | 799 | 462 | 738 | 82 | 176 | 101 | 209 | 75 | 157 | 91 | 175 |
| Investment income | 1,319 | 2,525 | 1,329 | 2,484 | 1,159 | 2,209 | 1,159 | 2,142 | 160 | 317 | 170 | 341 | 219 | 429 | 232 | 456 |
| Insurance finance expenses | -783 | -1,551 | -767 | -1,538 | -705 | -1,410 | -697 | -1,405 | -78 | -140 | -69 | -133 | -144 | -272 | -141 | -281 |
| Other revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt financing charges | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying earnings before tax | 2,061 | 4,070 | 2,209 | 4,229 | 1,634 | 3,145 | 1,699 | 3,219 | 427 | 925 | 510 | 1,010 | 252 | 552 | 328 | 666 |
| Tax | -412 | -874 | -462 | -800 | -316 | -635 | -329 | -584 | -96 | -239 | -133 | -216 | -46 | -111 | -64 | -110 |
| Income from affiliates & other | 103 | 186 | 101 | 157 | 101 | 182 | 93 | 154 | 2 | 4 | 8 | 2 | — | — | — | — |
| Minority interests | -27 | -60 | -34 | -85 | -27 | -56 | -30 | -75 | 0 | -4 | -3 | -9 | — | — | — | — |
| Underlying earnings group share | 1,725 | 3,323 | 1,814 | 3,501 | 1,392 | 2,636 | 1,433 | 2,715 | 333 | 687 | 381 | 787 | 205 | 441 | 264 | 556 |
| Closing invested assets | 329,460 | 345,008 | 338,447 | 334,840 | — | — | — | — | — | — | — | — | — | — | — | — |
| o/w VFA | 234,783 | 230,205 | 229,844 | 226,937 | — | — | — | — | — | — | — | — | — | — | — | — |
| o/w non VFA | 94,677 | 114,803 | 108,603 | 107,903 | — | — | — | — | — | — | — | — | — | — | — | — |
| For short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Liabilities for remaining coverage net of reinsurance | 2,446 | 2,096 | 2,856 | 2,511 | 157 | 96 | 105 | 21 | 2,289 | 2,000 | 2,750 | 2,490 | — | — | — | — |
| Best estimate for incurred claims net of reinsurance | 13,876 | 14,162 | 13,960 | 14,592 | 11,589 | 11,778 | 11,623 | 11,205 | 2,286 | 2,384 | 2,337 | 3,386 | — | — | — | — |
| For long-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Best Estimate Liabilities net of reinsurance | 295,342 | 306,249 | 301,040 | 300,391 | 275,276 | 285,391 | 280,314 | 280,280 | 20,066 | 20,858 | 20,726 | 20,112 | — | — | — | — |
| o/w VFA Gross of reinsurance | 264,013 | 273,094 | 266,960 | 271,902 | 243,037 | 251,273 | 244,964 | 250,326 | 20,977 | 21,821 | 21,996 | 21,576 | — | — | — | — |
| o/w BBA Gross of reinsurance | 50,097 | 51,845 | 51,524 | 45,307 | 50,917 | 52,713 | 52,731 | 46,724 | -821 | -868 | -1,207 | -1,417 | — | — | — | — |
| o/w Reinsurance | -18,768 | -18,690 | -17,443 | -16,817 | -18,679 | -18,595 | -17,381 | -16,770 | -90 | -95 | -62 | -47 | — | — | — | — |
L&H UE by Geography
| EUR million | Total | France | Europe | AXA XL | Asia, Africa & EME-LATAM | Transversal & Other | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 |
| Short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Revenues | 7,979 | 16,207 | 8,512 | 17,416 | 4,654 | 9,503 | 4,870 | 9,787 | 1,778 | 3,604 | 2,051 | 4,419 | 0 | 0 | 0 | 0 | 1,457 | 2,925 | 1,503 | 3,037 | 90 | 174 | 88 | 172 |
| Combined ratio | 97.6% | 97.4% | 97.1% | 97.2% | 96.7% | 97.3% | 97.4% | 97.3% | 98.8% | 96.9% | 96.4% | 94.8% | 0.0% | 0.0% | 0.0% | 0.0% | 99.1% | 99.1% | 97.6% | 101.3% | 92.2% | 89.1% | 83.6% | 86.7% |
| Technical margin | 195 | 415 | 248 | 479 | 155 | 258 | 124 | 265 | 21 | 113 | 73 | 230 | 0 | 0 | 0 | 0 | 13 | 26 | 36 | -39 | 7 | 19 | 14 | 23 |
| Long-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CSM release | 1,395 | 2,775 | 1,428 | 2,954 | 407 | 823 | 419 | 895 | 468 | 920 | 471 | 984 | 4 | 3 | 0 | 1 | 516 | 1,029 | 538 | 1,074 | 0 | 0 | 0 | 0 |
| Technical experience | -64 | -95 | -30 | -150 | -40 | -96 | -37 | -81 | -11 | -8 | 8 | -70 | 3 | 2 | 0 | -5 | -17 | 7 | -1 | 6 | 0 | 0 | 0 | 0 |
| Actual vs. expected cash flows | 9 | -15 | 12 | 39 | 8 | -8 | 2 | 15 | 5 | -11 | -11 | -6 | -2 | -3 | -1 | -6 | 0 | 8 | 22 | 35 | 0 | 0 | 0 | 0 |
| Risk adjustment release | 30 | 59 | 44 | 72 | 5 | 15 | 9 | 14 | 11 | 21 | 21 | 32 | 0 | 1 | 0 | 1 | 13 | 23 | 13 | 25 | 0 | 0 | 0 | 0 |
| Changes in onerous contracts | -32 | 6 | -12 | -29 | 0 | 0 | 0 | 0 | -33 | -25 | -13 | -36 | 5 | 5 | 0 | 0 | -3 | 26 | 1 | 7 | 0 | 0 | 0 | 0 |
| Other long-term | -72 | -145 | -74 | -232 | -52 | -103 | -49 | -111 | 7 | 7 | 12 | -61 | 0 | 0 | 0 | 0 | -26 | -50 | -37 | -61 | 0 | 0 | 0 | 0 |
| Financial result & other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result | 536 | 975 | 563 | 946 | 100 | 192 | 118 | 197 | 284 | 504 | 269 | 477 | 10 | 19 | 10 | 20 | 142 | 260 | 165 | 250 | 0 | 0 | 0 | 2 |
| Investment income | 1,319 | 2,525 | 1,329 | 2,484 | 370 | 701 | 370 | 703 | 490 | 916 | 478 | 889 | 13 | 27 | 14 | 27 | 446 | 882 | 467 | 862 | 0 | 0 | 0 | 2 |
| Insurance finance expenses | -783 | -1,551 | -767 | -1,538 | -270 | -509 | -252 | -507 | -206 | -412 | -209 | -411 | -3 | -7 | -4 | -8 | -303 | -622 | -301 | -612 | 0 | 0 | 0 | 0 |
| Other revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt financing charges | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying earnings before tax | 2,061 | 4,070 | 2,209 | 4,229 | 622 | 1,176 | 624 | 1,276 | 762 | 1,529 | 821 | 1,622 | 17 | 25 | 10 | 16 | 654 | 1,322 | 739 | 1,291 | 7 | 19 | 14 | 25 |
| Tax | -412 | -874 | -462 | -800 | -106 | -220 | -100 | -237 | -180 | -376 | -176 | -285 | -3 | 0 | -2 | -4 | -123 | -277 | -182 | -272 | 0 | 0 | -1 | -4 |
| Income from affiliates & other | 103 | 186 | 101 | 157 | 4 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100 | 177 | 101 | 157 | 0 | 0 | 0 | 0 |
| Minority interests | -27 | -60 | -34 | -85 | 0 | 0 | 0 | 0 | -23 | -49 | -28 | -74 | 0 | 0 | 0 | 0 | -4 | -12 | -5 | -11 | 0 | 0 | 0 | 0 |
| Underlying earnings group share | 1,725 | 3,323 | 1,814 | 3,501 | 519 | 964 | 524 | 1,039 | 559 | 1,104 | 616 | 1,264 | 14 | 25 | 8 | 12 | 627 | 1,211 | 653 | 1,165 | 7 | 19 | 14 | 22 |
| For short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Liabilities for remaining coverage net of reinsurance | 2,446 | 2,096 | 2,856 | 2,511 | 50 | -2 | 28 | -6 | 1,228 | 967 | 1,619 | 1,352 | 0 | 0 | 0 | 0 | 1,159 | 1,124 | 1,204 | 1,155 | 9 | 6 | 5 | 10 |
| Best estimate for incurred claims net of reinsurance | 13,876 | 14,162 | 13,960 | 14,592 | 12,589 | 12,831 | 12,443 | 12,850 | 773 | 871 | 1,015 | 1,186 | 0 | 0 | 0 | 0 | 501 | 447 | 487 | 541 | 13 | 14 | 15 | 15 |
| For long-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Best estimate liabilities net of reinsurance | 295,342 | 306,249 | 301,040 | 300,391 | 112,949 | 115,280 | 114,525 | 114,424 | 135,034 | 139,257 | 137,584 | 136,725 | 324 | 345 | 310 | 309 | 47,035 | 51,368 | 48,620 | 48,934 | 0 | 0 | 0 | 0 |
| o/w VFA gross of reinsurance | 264,013 | 273,094 | 266,960 | 271,902 | 116,132 | 117,942 | 116,770 | 117,266 | 121,623 | 125,513 | 121,135 | 122,782 | 0 | 0 | 0 | 0 | 26,258 | 29,639 | 29,055 | 31,854 | 0 | 0 | 0 | 0 |
| o/w BBA gross of reinsurance | 50,097 | 51,845 | 51,524 | 45,307 | 9,606 | 10,019 | 9,848 | 8,873 | 13,520 | 13,810 | 16,410 | 13,760 | 1,670 | 1,659 | 1,522 | 1,473 | 25,301 | 26,356 | 23,743 | 21,201 | 0 | 0 | 0 | 0 |
| o/w Reinsurance | -18,768 | -18,690 | -17,443 | -16,817 | -12,790 | -12,682 | -12,093 | -11,715 | -108 | -66 | 39 | 183 | -1,346 | -1,315 | -1,212 | -1,164 | -4,524 | -4,627 | -4,178 | -4,121 | 0 | 0 | 0 | 0 |
Life UE by Geography
| EUR million | Total | France | Europe | AXA XL | Asia, Africa & EME-LATAM | Transversal & Other | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 |
| Short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Revenues | 2,112 | 4,247 | 2,211 | 4,444 | 1,902 | 3,843 | 2,005 | 4,044 | 53 | 109 | 54 | 106 | 0 | 0 | 0 | 0 | 157 | 296 | 152 | 295 | 0 | 0 | 0 | 0 |
| Combined ratio | 94.5% | 95.5% | 95.2% | 95.4% | 95.1% | 96.3% | 95.9% | 96.1% | 79.8% | 77.0% | 79.0% | 77.3% | 0.0% | 0.0% | 0.0% | 0.0% | 92.3% | 91.5% | 91.5% | 91.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Technical margin | 116 | 191 | 107 | 206 | 93 | 141 | 83 | 158 | 11 | 25 | 11 | 24 | 0 | 0 | 0 | 0 | 12 | 25 | 13 | 25 | 0 | 0 | 0 | 0 |
| Long-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CSM release | 1,136 | 2,253 | 1,158 | 2,415 | 407 | 823 | 419 | 895 | 390 | 759 | 386 | 804 | 4 | 3 | 0 | 1 | 336 | 669 | 353 | 715 | 0 | 0 | 0 | 0 |
| Technical experience | -71 | -98 | -28 | -139 | -40 | -96 | -37 | -81 | -4 | 12 | 13 | -53 | 3 | 2 | 0 | -5 | -30 | -16 | -4 | 0 | 0 | 0 | 0 | 0 |
| Actual vs. expected cash flows | -4 | -33 | 10 | 37 | 8 | -8 | 2 | 15 | 3 | -11 | -11 | -6 | -2 | -3 | -1 | -6 | -12 | -10 | 20 | 33 | 0 | 0 | 0 | 0 |
| Risk adjustment release | 25 | 51 | 37 | 59 | 5 | 15 | 9 | 14 | 12 | 23 | 20 | 30 | 0 | 1 | 0 | 1 | 8 | 13 | 8 | 14 | 0 | 0 | 0 | 0 |
| Changes in onerous contracts | -30 | 9 | -10 | -25 | 0 | 0 | 0 | 0 | -32 | -23 | -13 | -33 | 5 | 5 | 0 | 0 | -3 | 26 | 3 | 8 | 0 | 0 | 0 | 0 |
| Other long-term | -63 | -124 | -65 | -211 | -52 | -103 | -49 | -111 | 13 | 23 | 17 | -44 | 0 | 0 | 0 | 0 | -23 | -45 | -34 | -55 | 0 | 0 | 0 | 0 |
| Financial result & other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result | 454 | 799 | 462 | 738 | 103 | 193 | 114 | 185 | 249 | 432 | 232 | 401 | 10 | 19 | 10 | 20 | 92 | 155 | 105 | 132 | 0 | 0 | 0 | 0 |
| Investment income | 1,159 | 2,209 | 1,159 | 2,142 | 344 | 660 | 346 | 649 | 451 | 838 | 438 | 809 | 13 | 27 | 14 | 27 | 350 | 684 | 361 | 657 | 0 | 0 | 0 | 0 |
| Insurance finance expenses | -705 | -1,410 | -697 | -1,405 | -241 | -467 | -232 | -464 | -202 | -407 | -206 | -408 | -3 | -7 | -4 | -8 | -259 | -530 | -256 | -525 | 0 | 0 | 0 | 0 |
| Other revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt financing charges | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying earnings before tax | 1,634 | 3,145 | 1,699 | 3,219 | 563 | 1,060 | 579 | 1,156 | 645 | 1,227 | 643 | 1,176 | 17 | 25 | 10 | 16 | 409 | 833 | 468 | 872 | 0 | 0 | 0 | 0 |
| Tax | -316 | -635 | -329 | -584 | -96 | -194 | -93 | -213 | -148 | -289 | -131 | -183 | -3 | 0 | -2 | -4 | -68 | -152 | -103 | -184 | 0 | 0 | 0 | 0 |
| Income from affiliates & other | 101 | 182 | 93 | 154 | 4 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 97 | 173 | 93 | 154 | 0 | 0 | 0 | 0 |
| Minority interests | -27 | -56 | -30 | -75 | 0 | 0 | 0 | 0 | -23 | -47 | -28 | -70 | 0 | 0 | 0 | 0 | -4 | -9 | -3 | -5 | 0 | 0 | 0 | 0 |
| Underlying earnings group share | 1,392 | 2,636 | 1,433 | 2,715 | 470 | 875 | 486 | 943 | 474 | 891 | 484 | 923 | 14 | 25 | 8 | 12 | 434 | 845 | 456 | 837 | 0 | 0 | 0 | 0 |
| For short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Liabilities for remaining coverage net of reinsurance | 157 | 96 | 105 | 21 | 23 | -19 | 4 | -41 | -3 | -14 | -35 | -24 | 0 | 0 | 0 | 0 | 137 | 129 | 137 | 86 | 0 | 0 | 0 | 0 |
| Best estimate for incurred claims net of reinsurance | 11,589 | 11,778 | 11,623 | 11,205 | 11,349 | 11,502 | 11,352 | 10,939 | 75 | 120 | 118 | 124 | 0 | 0 | 0 | 0 | 165 | 157 | 154 | 142 | 0 | 0 | 0 | 0 |
| For long-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Best estimate liabilities net of reinsurance | 275,276 | 285,391 | 280,314 | 280,280 | 112,949 | 115,280 | 114,525 | 114,424 | 114,389 | 117,841 | 116,058 | 115,433 | 324 | 345 | 310 | 309 | 47,614 | 51,926 | 49,420 | 50,113 | 0 | 0 | 0 | 0 |
| o/w VFA gross of reinsurance | 243,037 | 251,273 | 244,964 | 250,326 | 116,132 | 117,942 | 116,770 | 117,266 | 100,727 | 103,800 | 99,267 | 101,144 | 0 | 0 | 0 | 0 | 26,178 | 29,530 | 28,928 | 31,916 | 0 | 0 | 0 | 0 |
| o/w BBA gross of reinsurance | 50,917 | 52,713 | 52,731 | 46,724 | 9,606 | 10,019 | 9,848 | 8,873 | 13,770 | 14,107 | 16,752 | 14,106 | 1,670 | 1,659 | 1,522 | 1,473 | 25,871 | 26,927 | 24,608 | 22,272 | 0 | 0 | 0 | 0 |
| o/w Reinsurance | -18,679 | -18,595 | -17,381 | -16,770 | -12,790 | -12,682 | -12,093 | -11,715 | -108 | -66 | 39 | 183 | -1,346 | -1,315 | -1,212 | -1,164 | -4,435 | -4,532 | -4,116 | -4,074 | 0 | 0 | 0 | 0 |
Health UE by Geography
| EUR million | Total | France | Europe | AXA XL | Asia, Africa & EME-LATAM | Transversal & Other | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 | 1H24 | FY24 | 1H25 | FY25 |
| Short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Revenues | 5,867 | 11,960 | 6,301 | 12,972 | 2,752 | 5,661 | 2,865 | 5,744 | 1,725 | 3,495 | 1,997 | 4,314 | 0 | 0 | 0 | 0 | 1,300 | 2,629 | 1,350 | 2,742 | 90 | 174 | 88 | 172 |
| Combined ratio | 98.6% | 98.1% | 97.8% | 97.9% | 97.8% | 97.9% | 98.5% | 98.1% | 99.4% | 97.5% | 96.9% | 95.2% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 98.3% | 102.3% | 92.2% | 89.1% | 83.6% | 86.7% |
| Technical margin | 79 | 224 | 141 | 273 | 62 | 117 | 42 | 108 | 10 | 88 | 62 | 206 | 0 | 0 | 0 | 0 | 1 | 1 | 23 | -64 | 7 | 19 | 14 | 23 |
| Long-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| CSM release | 259 | 522 | 270 | 539 | 0 | 0 | 0 | 0 | 78 | 161 | 84 | 180 | 0 | 0 | 0 | 0 | 180 | 360 | 186 | 359 | 0 | 0 | 0 | 0 |
| Technical experience | 7 | 3 | -2 | -11 | 0 | 0 | 0 | 0 | -6 | -20 | -5 | -17 | 0 | 0 | 0 | 0 | 14 | 23 | 3 | 6 | 0 | 0 | 0 | 0 |
| Actual vs. expected cash flows | 13 | 18 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 18 | 2 | 2 | 0 | 0 | 0 | 0 |
| Risk adjustment release | 4 | 8 | 7 | 13 | 0 | 0 | 0 | 0 | 0 | -2 | 1 | 3 | 0 | 0 | 0 | 0 | 5 | 10 | 5 | 11 | 0 | 0 | 0 | 0 |
| Changes in onerous contracts | -1 | -2 | -2 | -4 | 0 | 0 | 0 | 0 | -1 | -2 | 0 | -3 | 0 | 0 | 0 | 0 | -1 | 0 | -1 | -1 | 0 | 0 | 0 | 0 |
| Other long-term | -8 | -21 | -9 | -22 | 0 | 0 | 0 | 0 | -6 | -16 | -6 | -16 | 0 | 0 | 0 | 0 | -2 | -5 | -3 | -5 | 0 | 0 | 0 | 0 |
| Financial result & other | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financial result | 82 | 176 | 101 | 209 | -3 | -1 | 4 | 12 | 35 | 72 | 37 | 76 | 0 | 0 | 0 | 0 | 51 | 105 | 60 | 118 | 0 | 0 | 0 | 2 |
| Investment income | 160 | 317 | 170 | 341 | 26 | 41 | 24 | 55 | 39 | 77 | 40 | 79 | 0 | 0 | 0 | 0 | 95 | 198 | 106 | 205 | 0 | 0 | 0 | 2 |
| Insurance finance expenses | -78 | -140 | -69 | -133 | -29 | -43 | -20 | -42 | -4 | -5 | -4 | -3 | 0 | 0 | 0 | 0 | -45 | -93 | -45 | -87 | 0 | 0 | 0 | 0 |
| Other revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt financing charges | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Underlying earnings before tax | 427 | 925 | 510 | 1,010 | 59 | 116 | 46 | 120 | 117 | 302 | 178 | 446 | 0 | 0 | 0 | 0 | 245 | 489 | 272 | 419 | 7 | 19 | 14 | 25 |
| Tax | -96 | -239 | -133 | -216 | -10 | -27 | -7 | -24 | -31 | -87 | -46 | -101 | 0 | 0 | 0 | 0 | -55 | -125 | -80 | -88 | 0 | 0 | -1 | -4 |
| Income from affiliates & other | 2 | 4 | 8 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 8 | 2 | 0 | 0 | 0 | 0 |
| Minority interests | 0 | -4 | -3 | -9 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | -4 | 0 | 0 | 0 | 0 | 0 | -3 | -3 | -6 | 0 | 0 | 0 | 0 |
| Underlying earnings group share | 333 | 687 | 381 | 787 | 49 | 89 | 39 | 96 | 85 | 213 | 132 | 341 | 0 | 0 | 0 | 0 | 192 | 366 | 197 | 328 | 7 | 19 | 14 | 22 |
| For short-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Liabilities for remaining coverage net of reinsurance | 2,289 | 2,000 | 2,750 | 2,490 | 27 | 18 | 24 | 35 | 1,231 | 981 | 1,654 | 1,375 | 0 | 0 | 0 | 0 | 1,022 | 995 | 1,067 | 1,069 | 9 | 6 | 5 | 10 |
| Best estimate for incurred claims net of reinsurance | 2,286 | 2,384 | 2,337 | 3,386 | 1,240 | 1,329 | 1,091 | 1,911 | 698 | 751 | 898 | 1,062 | 0 | 0 | 0 | 0 | 336 | 290 | 334 | 398 | 13 | 14 | 15 | 15 |
| For long-term business | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Best estimate liabilities net of reinsurance | 20,066 | 20,858 | 20,726 | 20,112 | 0 | 0 | 0 | 0 | 20,645 | 21,416 | 21,527 | 21,291 | 0 | 0 | 0 | 0 | -579 | -557 | -800 | -1,180 | 0 | 0 | 0 | 0 |
| o/w VFA gross of reinsurance | 20,977 | 21,821 | 21,996 | 21,576 | 0 | 0 | 0 | 0 | 20,896 | 21,713 | 21,868 | 21,637 | 0 | 0 | 0 | 0 | 81 | 109 | 128 | -62 | 0 | 0 | 0 | 0 |
| o/w BBA gross of reinsurance | -821 | -868 | -1,207 | -1,417 | 0 | 0 | 0 | 0 | -250 | -297 | -342 | -346 | 0 | 0 | 0 | 0 | -571 | -571 | -866 | -1,071 | 0 | 0 | 0 | 0 |
| o/w Reinsurance | -90 | -95 | -62 | -47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -90 | -95 | -62 | -47 | 0 | 0 | 0 | 0 |
Asset Management
| 1H24 | FY24 | 1H25 | FY25 (footnote: AXA IM FY contribution presented in this document corresponds to its effective contribution to the Group’s results over the period of time when it was consolidated, i.e. until 1st July 2025.) | |||||
|---|---|---|---|---|---|---|---|---|
| EUR million | Total | o/w third party | Total | o/w third party | Total | o/w third party | Total | o/w third party |
| Opening AUM (in EUR billion) | 843 | 332 | 843 | 332 | 879 | 356 | 879 | 356 |
| Net inflows | 7 | -1 | 3 | 4 | -3 | -10 | -3 | -10 |
| Scope & other | 0 | 10 | 2 | 21 | 0 | -6 | 0 | -6 |
| Market effect | 12 | 10 | 26 | 21 | -3 | -6 | -3 | -6 |
| Currency impact | -4 | 10 | 5 | 21 | -21 | -6 | -21 | -6 |
| Closing AUM (in EUR billion) | 859 | 340 | 879 | 356 | 853 | 341 | 853 | 341 |
| Alternatives | 227 | 86 | 229 | 90 | 233 | 95 | 233 | 95 |
| Core & other | 532 | 254 | 551 | 266 | 528 | 246 | 528 | 246 |
| Asian joint ventures | 101 | — | 99 | — | 92 | — | 92 | — |
| Gross revenues - after intercompany elimination | 787 | — | 1,701 | — | 875 | — | 875 | — |
| Gross revenues - before intercompany elimination | 937 | — | 2,004 | — | 1,018 | — | 1,018 | — |
| Management fees | 679 | 385 | 1,425 | 773 | 724 | 439 | 724 | 439 |
| Performance fees | 18 | 8 | 57 | 21 | 16 | 9 | 16 | 9 |
| Distribution fees | 205 | — | 409 | — | 231 | — | 231 | — |
| Other | 35 | — | 112 | — | 46 | — | 46 | — |
| General expenses | -698 | — | -1,493 | — | -793 | — | -793 | — |
| Distribution fees retroceded | -205 | — | -409 | — | -231 | — | -231 | — |
| Financial result | 24 | — | 35 | — | 14 | — | 14 | — |
| Underlying earnings before tax | 263 | — | 546 | — | 239 | — | 239 | — |
| Tax | -69 | — | -160 | — | -68 | — | -68 | — |
| Income from affiliates & other | 16 | — | 29 | — | 8 | — | 8 | — |
| Minority interests | -6 | — | -13 | — | -4 | — | -4 | — |
| Underlying earnings group share | 204 | — | 402 | — | 175 | — | 175 | — |
| Average assets under management (€bn) | 749 | — | 759 | — | 769 | — | 769 | — |
| Asset management fee bps | 18.1 bps | — | 18.8 bps | — | 18.8 bps | — | 18.8 bps | — |
| Underlying cost income ratio | 67.3% | — | 68.0% | — | 71.4% | — | 71.4% | — |
Holdings
| EUR million | 1H24 | FY24 | 1H25 | FY25 |
|---|---|---|---|---|
| Financial result | 181 | 402 | 228 | 422 |
| Other revenues (footnote: Includes liquid invested assets.) | 522 | 1,050 | 607 | 1,149 |
| Other expenses | -925 | -1,986 | -1,075 | -2,107 |
| Debt financing charges | -471 | -948 | -452 | -928 |
| Underlying earnings before tax | -693 | -1,482 | -692 | -1,464 |
| Tax | 100 | 324 | 101 | 284 |
| Income from affiliates & other | 0 | 0 | 0 | 0 |
| Minority interests | 0 | 0 | 0 | 0 |
| Underlying earnings group share | -592 | -1,157 | -591 | -1,180 |
Activity Indicators
| 1H24 | FY24 | 1H25 | FY25 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR million | Total | P&C | Life & Health | o/w employee benefits (footnote: Employee Benefits include Group Protection and Group Health contracts.) | Life | Health | Asset management | Bank | Total | P&C | Life & Health | o/w employee benefits (footnote: Employee Benefits include Group Protection and Group Health contracts.) | Life | Health | Asset management | Bank | Total | P&C | Life & Health | o/w employee benefits (footnote: Employee Benefits include Group Protection and Group Health contracts.) | Life | Health | Asset management | Bank | Total | P&C | Life & Health | o/w employee benefits (footnote: Employee Benefits include Group Protection and Group Health contracts.) | Life | Health | Asset management | Bank |
| Gross written premiums & other revenues | 59,872 | 32,522 | 26,505 | 6,673 | 17,419 | 9,086 | 787 | 57 | 110,316 | 56,514 | 51,983 | 12,167 | 34,497 | 17,486 | 1,701 | 118 | 64,251 | 34,097 | 29,230 | 7,223 | 19,081 | 10,149 | 875 | 49 | 115,524 | 58,038 | 56,512 | 12,867 | 37,499 | 19,014 | 875 | 99 |
| IFRS17/9 new business value (NBV) (a) | 1,206 | — | 1,206 | — | 953 | 253 | — | — | 2,264 | — | 2,264 | — | 1,792 | 473 | — | — | 1,189 | — | 1,189 | — | 928 | 260 | — | — | 2,233 | — | 2,233 | — | 1,747 | 486 | — | — |
| New business contractual service margin (NB CSM) | 1,131 | — | 1,131 | — | 919 | 213 | — | — | 2,169 | — | 2,169 | — | 1,770 | 399 | — | — | 1,184 | — | 1,184 | — | 950 | 234 | — | — | 2,199 | — | 2,199 | — | 1,822 | 377 | — | — |
| Other NBV (footnote: Includes expected profits from short term Life & Health business, carried by Life entities, Pure Investment Contracts, NBV from Equity method entities as well as New Business Loss Components and Margin ceded to reinsurers.) | 456 | — | 456 | — | 333 | 123 | — | — | 824 | — | 824 | — | 594 | 231 | — | — | 382 | — | 382 | — | 270 | 113 | — | — | 757 | — | 757 | — | 491 | 266 | — | — |
| Tax | -381 | — | -381 | — | -299 | -83 | — | — | -729 | — | -729 | — | -572 | -158 | — | — | -378 | — | -378 | — | -292 | -86 | — | — | -724 | — | -724 | — | -567 | -157 | — | — |
| Present value of expected premiums (PVEP) (b) | 25,588 | — | 25,588 | — | 18,234 | 7,354 | — | — | 50,896 | — | 50,896 | — | 36,860 | 14,036 | — | — | 25,918 | — | 25,918 | — | 19,487 | 6,430 | — | — | 49,357 | — | 49,357 | — | 37,103 | 12,254 | — | — |
| IFRS17/9 NBV margin (a)/(b) | 4.7% | — | 4.7% | — | 5.2% | 3.4% | — | — | 4.4% | — | 4.4% | — | 4.9% | 3.4% | — | — | 4.6% | — | 4.6% | — | 4.8% | 4.0% | — | — | 4.5% | — | 4.5% | — | 4.7% | 4.0% | — | — |
| 1H24 | FY24 | 1H25 | FY25 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR million | Total | France | Europe | AXA XL | Asia, Africa & EME-LATAM | AXA IM | Transversal & Other | Total | France | Europe | AXA XL | Asia, Africa & EME-LATAM | AXA IM | Transversal & Other | Total | France | Europe | AXA XL | Asia, Africa & EME-LATAM | AXA IM | Transversal & Other | Total | France | Europe | AXA XL | Asia, Africa & EME-LATAM | AXA IM | Transversal & Other |
| Gross written premiums & other revenues | 59,872 | 14,719 | 22,579 | 11,220 | 9,571 | 787 | 995 | 110,316 | 28,996 | 39,298 | 19,383 | 19,083 | 1,701 | 1,856 | 64,251 | 15,670 | 24,649 | 11,749 | 10,302 | 875 | 1,006 | 115,524 | 30,598 | 43,005 | 19,277 | 19,925 | 875 | 1,844 |
| IFRS17/9 new business value (NBV) (a) | 1,206 | 354 | 348 | — | 504 | — | — | 2,264 | 682 | 597 | — | 986 | — | — | 1,189 | 315 | 364 | — | 510 | — | — | 2,233 | 695 | 578 | — | 959 | — | — |
| New business contractual service margin (NB CSM) | 1,131 | 203 | 398 | — | 531 | — | — | 2,169 | 391 | 731 | — | 1,047 | — | — | 1,184 | 199 | 443 | — | 541 | — | — | 2,199 | 431 | 740 | — | 1,028 | — | — |
| Other NBV (footnote: Includes expected profits from short term Life & Health business, carried by Life entities, Pure Investment Contracts, NBV from Equity method entities as well as New Business Loss Components and Margin ceded to reinsurers.) | 456 | 275 | 50 | — | 131 | — | — | 824 | 528 | 49 | — | 247 | — | — | 382 | 225 | 28 | — | 129 | — | — | 757 | 506 | 12 | — | 239 | — | — |
| Tax | -381 | -123 | -100 | — | -158 | — | — | -729 | -237 | -184 | — | -309 | — | — | -378 | -109 | -107 | — | -161 | — | — | -724 | -242 | -174 | — | -308 | — | — |
| Present value of expected premiums (PVEP) (b) | 25,588 | 12,301 | 6,317 | — | 6,971 | — | — | 50,896 | 25,370 | 11,831 | — | 13,695 | — | — | 25,918 | 11,662 | 6,843 | — | 7,413 | — | — | 49,357 | 22,858 | 12,651 | — | 13,847 | — | — |
| IFRS17/9 NBV margin (a)/(b) | 4.7% | 2.9% | 5.5% | — | 7.2% | — | — | 4.4% | 2.7% | 5.0% | — | 7.2% | — | — | 4.6% | 2.7% | 5.3% | — | 6.9% | — | — | 4.5% | 3.0% | 4.6% | — | 6.9% | — | — |
Balance Sheet
| EUR billion | FY24 | FY25 |
|---|---|---|
| Goodwill | 18.1 | 17.8 |
| Other intangible assets | 4.4 | 4.4 |
| Total intangible assets | 22.6 | 22.2 |
| Investments in real estate properties | 29.2 | 27.8 |
| Financial investments | 418.2 | 401.8 |
| Unit-linked assets | 90.1 | 97.2 |
| Total investments from insurance activities | 537.5 | 526.9 |
| Investments from non-insurance activities | 18.5 | 16.6 |
| Equity method investments | 1.5 | 1.5 |
| Assets arising from insurance and reinsurance contracts held | 26.1 | 23.9 |
| Present value of future cash flows | 24.1 | 22.0 |
| Contractual service margin | 1.4 | 1.4 |
| Risk adjustment | 0.5 | 0.5 |
| Receivables and other assets | 24.1 | 21.9 |
| Assets held for sale | 4.5 | 0.2 |
| Cash and cash equivalents | 19.0 | 22.2 |
| Total assets | 653.8 | 635.5 |
| EUR billion | FY24 | FY25 |
|---|---|---|
| Shareholders' equity group share | 49.9 | 47.2 |
| Non-controlling interests | 2.5 | 2.4 |
| Shareholders' equity | 52.5 | 49.6 |
| Financing debt | 14.4 | 15.8 |
| Liabilities arising from insurance contracts and investment contracts with discretionary participation features contracts | 477.0 | 470.4 |
| Present value of future cash flows | 438.4 | 432.6 |
| Contractual service margin | 35.3 | 34.7 |
| Risk adjustment | 3.3 | 3.1 |
| Other investment contract liabilities | 12.6 | 12.8 |
| Liabilities arising from insurance, reinsurance and investment contracts | 489.6 | 483.2 |
| Liabilities arising from non-insurance activities | 10.1 | 9.9 |
| Provisions for risks and charges | 4.9 | 4.6 |
| Payables and other liabilities | 80.9 | 72.5 |
| Liabilities held for sale | 1.4 | 0.0 |
| Total liabilities, non-controlling interests and shareholders' equity | 653.8 | 635.5 |
CSM rollforward
| EUR million | FY23 restated | New business CSM | Underlying return on inforce | CSM release | Economic variance | Operating variance | Other (footnote: Including scope changes and FX. ** Following the termination of the sale of a closed life and pensions portfolio at AXA Germany in 2024. It was classified as held for sale in 2023.) | FY24 |
|---|---|---|---|---|---|---|---|---|
| Total group (pre-tax) | 34,187 | 2,169 | 1,383 | -2,775 | -998 | 432 | -545 | 33,853 |
| P&C | 206 | 0 | 0 | 0 | 0 | 0 | 76 | 282 |
| Life | 26,200 | 1,770 | 1,172 | -2,253 | -890 | 363 | -534 | 25,826 |
| Health | 7,782 | 400 | 211 | -522 | -108 | 69 | -87 | 7,744 |
| Total group (post-tax) | 26,777 | — | — | — | — | — | — | 26,320 |
| EUR million | FY24 | New business CSM | Underlying return on inforce | CSM release | Economic variance | Operating variance | Other (footnote: Including scope changes and FX. ** Following the termination of the sale of a closed life and pensions portfolio at AXA Germany in 2024. It was classified as held for sale in 2023.) | FY25 |
|---|---|---|---|---|---|---|---|---|
| Total group (pre-tax) | 33,853 | 2,199 | 1,328 | -2,954 | 594 | -316 | -1,451 | 33,253 |
| P&C | 282 | 0 | 0 | 0 | 0 | 0 | -21 | 261 |
| Life | 25,826 | 1,822 | 1,150 | -2,415 | 487 | -526 | -903 | 25,442 |
| Health | 7,744 | 377 | 178 | -539 | 107 | 210 | -527 | 7,550 |
| Total group (post-tax) | 26,320 | — | — | — | — | — | — | 25,864 |
Invested Assets
| EUR billion | Fair value | Asset allocation % | o/w participating |
|---|---|---|---|
| General account invested assets1 (footnote: 1 Reflects the fair value of assets excluding the minority interest share in assets held in fully consolidated invested funds, hedging derivatives, Unit-linked assets and investments from non-insurance activities.) | 450 | — | 60% |
| Fixed income | 345 | 77% | 60% |
| Government bonds | 167 | 37% | 66% |
| Corporate bonds and loans | 121 | 27% | 55% |
| Other fixed income | 56 | 13% | 52% |
| Asset backed securities2 (footnote: 2 Includes 91% of CLOs.) | 25 | 6% | 48% |
| Mortgage loans3 (footnote: 3 Residential loans (Euro 16 billion), Agency Pools (Euro 8 billion), and Commercial & agricultural loans (Euro 7 billion).) | 31 | 7% | 56% |
| Real estate | 41 | 9% | 63% |
| Infrastructure equity | 10 | 2% | 64% |
| Listed equities4 (footnote: 4 Includes hedges. Listed equities excluding hedges at Euro 14 billion (basis for % of participating).) | 10 | 2% | 82% |
| Private equity & hedge funds5 (footnote: 5 Private Equity (Euro 17 billion), Hedge Funds (Euro 5 billion) and Non-listed Equities (Euro 1 billion).) | 23 | 5% | 55% |
| Cash | 19 | 4% | 50% |
| Policy loans | 2 | 0% | 51% |
| EUR billion | Fair value by rating | ||||||
|---|---|---|---|---|---|---|---|
| — | Average rating | AAA | AA | A | BBB | Below investment grade | Non rated |
| -0.4 yr | — | — | — | — | — | — | — |
| — | AA | 27% | 31% | 28% | 10% | 2% | 2% |
| — | A | 16% | 6% | 39% | 28% | 11% | — |
| — | — | 54% | 28% | 10% | 3% | 1% | 4% |
Supplementary Info on Asset
| EUR billion | Fair value | Belgium | France | Germany | Italy | Japan | Netherlands | Spain | Switzerland | United States | Other EU countries | Supranational | Rest of the world |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breakdown by geographical exposure | 167 | 6% | 12% | 6% | 5% | 8% | 3% | 6% | 9% | 10% | 8% | 13% | 15% |
| EUR billion | Fair value | Basic materials | Communications | Consumer, cyclical | Consumer, non-cyclical | Covered and senior secured bonds | Energy | Financials | Industrial | Technology | Utilities | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breakdown by industry | 121 | 2% | 6% | 4% | 11% | 29% | 1% | 28% | 6% | 2% | 8% | 3% |
| EUR billion | Total | Banks | Non-banks1 (footnote: 1 Includes REITS corporate bonds (Euro 3 billion).) |
|---|---|---|---|
| Total | 33.4 | 27.5 | 6.0 |
| Senior unsecured bonds | 29.8 | 24.3 | 5.5 |
| Subordinated bonds2 (footnote: 2 Includes AT1 (Euro 0.4 billion).) | 3.0 | 2.7 | 0.4 |
| Other | 0.6 | 0.5 | 0.1 |
| EUR billion | Fair value | Belgium | France | Germany | Japan | Netherlands | Switzerland | United States | Other EU countries | Rest of the world |
|---|---|---|---|---|---|---|---|---|---|---|
| Breakdown by asset domiciliation | 10 | 3% | 7% | 3% | 7% | 2% | 4% | 37% | 9% | 27% |
| EUR billion | Fair value | Basic materials | Communications | Consumer, cyclical | Consumer, non-cyclical | Diversified | Energy | Financials | Funds | Industrial | Technology | Utilities | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breakdown by industry | 10 | 5% | 11% | 9% | 14% | 3% | 0% | 20% | 6% | 12% | 17% | 1% | 0% |
| EUR billion | Fair value | Belgium | France | Germany | Italy | Japan | Spain | Switzerland | United Kingdom | United States | Other EU countries | Rest of the world |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breakdown by geographical exposure | 41 | 5% | 25% | 11% | 3% | 5% | 4% | 13% | 7% | 12% | 5% | 10% |
| EUR billion | Fair value | Office | Residential | Industrial-logistic | Retail | Others |
|---|---|---|---|---|---|---|
| Breakdown by type | 41 | 33% | 22% | 15% | 12% | 18% |
| EUR billion | Fair value | Europe | Japan | United States | Other |
|---|---|---|---|---|---|
| Breakdown by asset domiciliation | 17 | 45% | 5% | 46% | 5% |
| EUR billion | Fair value | Residential | Commercial |
|---|---|---|---|
| Breakdown by type | 23 | 69% | 31% |
| EUR billion | FY25 |
|---|---|
| Shareholders' equity at beginning of the period (footnote: Shareholders' equity excludes the other comprehensive income as well as the undated and deeply subordinated debt.) | 49.9 |
| Paid-in capital | -4.9 |
| Treasury shares | -0.1 |
| Other comprehensive income arising from defined benefit plans | -0.3 |
| Fair value recorded in shareholders' equity | 1.3 |
| Other comprehensive income related to invested assets | -4.2 |
| Other comprehensive income related to (re) insurance contracts | 5.4 |
| Impact of currency fluctuations | -3.5 |
| Undated subordinated debt (including interest charges) | -0.3 |
| Realized gains on equity through retained earnings | 0.1 |
| Dividends | -4.6 |
| Net income for the period | 9.8 |
| Other | -0.2 |
| Shareholders' equity at end of the period (footnote: Shareholders' equity excludes the undated and deeply subordinated debt. CSM is net of tax and Group Share.) | 47.2 |
| EUR billion | FY24 | FY25 |
|---|---|---|
| Paid-in capital | 21.8 | 16.9 |
| Treasury shares | -1.5 | -1.6 |
| Other comprehensive income arising from defined benefit plans | -2.4 | -2.8 |
| Other comprehensive income | -8.1 | -6.8 |
| Other comprehensive income related to invested assets | -13.1 | -17.3 |
| Other comprehensive income related to (re) insurance contracts | 5.0 | 10.5 |
| Translation reserves | -1.1 | -4.6 |
| Undated subordinated debt | 4.8 | 4.6 |
| Retained earnings | 36.5 | 41.4 |
| Total shareholders' equity at the end of the period | 49.9 | 47.2 |
| EUR billion | FY24 | FY25 |
|---|---|---|
| Government bonds (recyclable) | -7.5 | -13.0 |
| Corporate bonds (recyclable) | -4.1 | -3.0 |
| Cash flow hedges (recyclable) | -3.5 | -3.3 |
| Equities (non-recyclable) | 2.3 | 2.1 |
| Others (recyclable) | -0.3 | -0.1 |
| Total other comprehensive income related to invested assets | -13.1 | -17.3 |
| Real estate | 6.7 | 6.5 |
| Other invested assets not included in shareholders' equity | -0.6 | -0.1 |
| Total unrealized gains and losses on invested assets at cost (net of tax) | 6.1 | 6.4 |
| Total unrealized gains and losses on invested assets (net of tax) | -7.0 | -10.9 |
RoE & Gearing
| EUR billion | FY24 | FY25 | Change in % points (FY25 vs FY24) |
|---|---|---|---|
| Net income ROE | 14.8% | 18.8% | 3.9 pt |
| Net income (a) (footnote: Including adjustments to reflect net financial charges related to undated and deeply subordinated debt (recorded through shareholders' equity).) | 7.7 | 9.6 | — |
| Average adjusted shareholders' equity (b) (footnote: Excluding reserves for Other Comprehensive Income as well as undated and deeply subordinated debt (recorded through shareholders' equity).) | 51.8 | 51.3 | — |
| Underlying ROE | 15.2% | 16.0% | 0.8 pt |
| Underlying earnings (a) | 7.9 | 8.2 | — |
| Average adjusted shareholders' equity (b) | 51.8 | 51.3 | — |
| EUR billion | FY24 | FY25 |
|---|---|---|
| Financing debt | 3.2 | 3.2 |
| Financing debt instrument issued | 3.2 | 3.2 |
| Financing debt owed to credit institutions | 0.0 | 0.0 |
| Dated subordinated debt | 11.2 | 12.6 |
| Reversal of mark-to-market of interest rates derivatives | -0.1 | -0.1 |
| Total gross debt (A) | 14.3 | 15.7 |
| Undated deeply subordinated notes (TSS) | 2.9 | 4.3 |
| Deeply subordinated notes (TSDI) | 1.9 | 0.3 |
| Total gross debt incl. undated and deeply subordinated notes (B) | 19.2 | 20.3 |
| Shareholders' equity (including non-controlling interests) (a) (C) (footnote: Shareholders' equity includes undated and deeply subordinated debts.) | 52.5 | 49.6 |
| Contractual service margin net of tax (D) | 26.3 | 25.9 |
| Shareholders' equity + contractual service margin + gross debt (E) = (C) + (D) + (A) | 93.1 | 91.1 |
| Debt gearing (G) = (B) / (E) | 20.6% | 22.3% |
Information on Solvency II
| EUR billion | FY24 | Regulatory & model changes | Normalized capital generation | Operating variance | Economic variance (incl. FX) | Dividend & share buy-backs | Debt | M&A, in-force and other | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Eligible own fund (EOF) | 55.9 | 0.2 | 8.8 | -0.4 | -2.1 | -6.0 | 1.6 | -1.7 | 56.4 |
| Solvency capital requirement (SCR) | 25.9 | 0.0 | 0.6 | 0.0 | -1.2 | 0.0 | 0.0 | -0.2 | 25.2 |
| Solvency II ratio | 216% | 0% | 28% | -1% | 4% | -24% | 6% | -5% | 224% |
| EUR billion | Total | Unrestricted tier | Restricted tier | Tier | |
|---|---|---|---|---|---|
| EOF as of FY25 | 56.4 | 39.6 | 4.7 | 11.6 | 0.4 |
| Insurance sector | 55.1 | 38.4 | 4.7 | 11.6 | 0.4 |
| Ancillary | — | — | — | — | — |
| Subject to transitional measures (footnote: Transitional measures on basic own funds applied on subordinated debts eligible under Solvency I regulation. These subordinated debts were also eligible under Solvency II until December 31, 2025. They are no longer eligible since January 1, 2026.) | 2.4 | — | 1.4 | 1.0 | — |
| Other financial sectors | 1.2 | 1.2 | — | — | — |
| EOF as of FY24 | 55.9 | 40.0 | 4.9 | 10.2 | 0.8 |
| Insurance sector | 53.5 | 37.5 | 4.9 | 10.2 | 0.8 |
| Ancillary | — | — | — | — | — |
| Subject to transitional measures (footnote: Transitional measures on basic own funds applied on subordinated debts eligible under Solvency I regulation. These subordinated debts were also eligible under Solvency II until December 31, 2025. They are no longer eligible since January 1, 2026.) | 4.5 | — | 3.4 | 1.1 | — |
| Other financial sectors | 2.5 | 2.5 | — | — | — |
| EUR billion | FY24 | FY25 |
|---|---|---|
| Interest rate +50 bps | +2 pts | +2 pts |
| Interest rate -50 bps | -4 pts | -1 pt |
| Corporate spread +50bps | -1 pt | -1 pt |
| Euro government spreads +50bps | -10 pts | -7 pts |
| Credit migration +20% | -4 pts | -4 pts |
| Listed equities +25% | +0 pt | -1 pt |
| Listed equities -25% | -3 pts | +2 pts |
| Private and infrastructure equity +25% | +13 pts | +14 pts |
| Private and infrastructure equity -25% | -15 pts | -19 pts |
| Inflation swap curve +50bps | -6 pts | -5 pts |
IFRS17 SHE to Group EOF
| EUR billion | FY25 |
|---|---|
| IFRS shareholders' equity | 49.6 |
| Contractual service margin (net of tax) | 25.9 |
| IFRS shareholders' equity inc. CSM | 75.5 |
| Net URCG not included in shareholders' equity | 6.4 |
| Elimination undated subordinated debts | -4.6 |
| Elimination intangibles | -21.3 |
| Goodwill | -17.8 |
| Others | -3.5 |
| IFRS tangible net asset value | 56.0 |
| Foreseeable dividends and distribution | -6.3 |
| Technical provision adjustments | -9.6 |
| Risk margin vs risk adjustment | -6.4 |
| BEL adjustment | -3.2 |
| Other adjustments | -0.6 |
| Unrestricted tier 1 | 39.6 |
| Restricted tier 1 + tier | 16.4 |
| Tier | 0.4 |
| Group eligible own funds | 56.4 |